



(11) **EP 2 881 461 A1**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
10.06.2015 Bulletin 2015/24

(51) Int Cl.:
C12N 5/071 (2010.01)

(21) Application number: **14192115.5**

(22) Date of filing: **21.11.2008**

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT
RO SE SI SK TR**

- **Arnold, Antje**
04107 Leipzig (DE)
- **Brown, Jeremy**
Falmouth, Cornwall TR11 3EW (GB)

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
08400048.8 / 2 192 174

(74) Representative: **Kilger, Ute**
Boehmert & Boehmert
Anwaltpartnerschaft mbB
Patentanwlte Rechtsanwälte
Pettenkoferstrasse 20-22
80336 Mnchen (DE)

(71) Applicant: **Fraunhofer-Gesellschaft zur Frderung
der
angewandten Forschung e.V.**
80686 Mnchen (DE)

Remarks:

This application was filed on 06-11-2014 as a
divisional application to the application mentioned
under INID code 62.

(72) Inventors:
• **Stolzing, Alexandra**
04103 Leipzig (DE)

(54) **Reprogramming cells toward a pluripotent state**

(57) The present invention relates to a process for preparing reprogrammed cells, in particular for preparing pluripotent and multipotent stem cells and to the pluripotent and multipotent stem cells prepared by said processes.

EP 2 881 461 A1

Description

[0001] The present invention relates to a process for preparing reprogrammed cells, in particular for preparing pluripotent and multipotent stem cells and to the pluripotent and multipotent stem cells prepared by said processes.

[0002] Aging - whether in vivo during the life course or in vitro during scale up - affects cells, in particular stem cells. For example, aged cells show increased apoptosis rates, decreased differentiation and proliferation capacity, and decreased therapeutic effectiveness. During aging, stem cells often differentiate into a less pliable, less proliferative form. Cell aging represents a problem in particular when using cells from elderly patients/donors as starting material for cell cultures, when expanding cells in vitro and when using cells that have a limited differentiation capacity for therapy or research.

[0003] One approach to dedifferentiate aged cells is to create so called Induced Pluripotent Stem Cells (IPS). The current state of the art foresees to use a viral transfer of transcription factors to induce increased differentiation potency in cells and to rejuvenate them. This, however, is potentially dangerous because a viral transfer permanently changes the genome of the cell and also might lead to complications because of the viral parts left behind in the cell genome. Moreover, viral integration into the genome is known to increase cancer risk in cells. Essentially the same applies to the use of plasmids for reprogramming cells (Okita et al., 2008, Science. 2008 Nov 7;322(5903):949-53. Generation of mouse induced pluripotent stem cells without viral vectors).

[0004] Another approach employs contacting cells to be reprogrammed with extracts of human embryonic stem cells for reprogramming cells. This approach, however, is ethically and practically problematic.

[0005] Some other approaches use chemical factors to dedifferentiate cells (e. g. US 200710254884 A1, US 200710020759 A1), but these factors are not efficacious in fully reprogramming cells to a pluripotent state by themselves.

[0006] Thus, the technical problem underlying the present invention is to provide improved methods to reprogram cells, in particular to dedifferentiate cells, which overcome the above-identified disadvantages, in particular allow in an easy, efficient and safe way the provision of reprogrammed, in particular dedifferentiated cells, preferably displaying multipotent, most preferably pluripotent, stem cell character.

[0007] The present invention solves its technical problem by the provision of a process for preparing reprogrammed cells in vitro, comprising the process steps, preferably in the given order, a) providing cells to be reprogrammed; b) introducing, preferably transfecting, mRNA molecules capable of reprogramming the cells into the cells provided in step a), wherein the reprogramming mRNA molecules are coding for at least one protein selected from the group consisting of: Ronin, Oct4, Klf4, Sox2, Nanog and TERT; and c) culturing the cells obtained in step b) in a cell culture medium and under a condition suitable to allow translation of the introduced, preferably transfected reprogramming mRNA molecules so as to obtain reprogrammed cells.

[0008] Thus, the present invention foresees a process which is able to prepare reprogrammed cells without the need to permanently change the genome of the cell and without the need to use viruses to transfer transcription factors or the like into the cell. The present invention also is advantageous in so far, as for reprogramming cells no extracts of human embryonic stem cells or cost intensive and potentially dangerous chemical factors are needed. Thus, ethical concerns, genetic stability problems and cancer risks are reduced or even avoided. In contrast, the present invention provides the advantageous teaching to introduce, preferably transfect, specific mRNA molecules, in the following termed "reprogramming mRNA molecules", into the cells, wherein these reprogramming mRNA molecules are able to reprogram the mRNA recipient cells, preferably the cells being transfected therewith, into a dedifferentiated status. Advantageously, the mRNA molecules introduced, preferably transfected, according to the present invention will not integrate into the recipient's genome and therefore do not pose a risk of cancer or genetic instability. The invention therefore foresees a process for preparing one or more reprogrammed cells in vitro wherein said process does not include any cloning amplification or proliferation of the mRNA recipient cells. The present invention also foresees a process for preparing one or more reprogrammed cells in vivo, that is in a living organ, a living organism or animal, more particular a mammal.

[0009] In the context of the present invention the term "reprogramming" preferably means remodelling, in particular erasing and/or remodelling, epigenetic marks of a cell such as DNA methylation, histon methylation or activating genes by inducing transcription factor signal systems as for oct4. In particular, the reprogramming of the present invention provides at least one dedifferentiated and/or rejuvenated cell, in particular provides a cell having the characteristic of a multipotent, in particular pluripotent stem cell. Thus, in case the cell to be reprogrammed is cells which already have a multipotent or pluripotent character, the present invention is able to maintain these cells by the reprogramming of the present invention in their multi- or pluripotent state for a prolonged period of time. In case the cells to be reprogrammed are in an aged or differentiated state, the present invention allows the dedifferentiation into a multipotent or pluripotent stem cell. In a particularly preferred embodiment, multipotent cells may be reprogrammed to become pluripotent cells.

[0010] In particular, the term "reprogrammed cells" designates cells which have been changed to have a higher differentiation and/or proliferation potential. Also, in a preferred embodiment the reprogramming of asomaticdifferentiated cell toward a multipotent stem cell or "young" differentiated cell is termed reprogramming and the product is called a reprogrammed cell.

[0011] In particular, the present process allows it to enrich immature stem cells, preferably showing a high telomerase activity, several multipotent, preferably pluripotency, markers and an increased secretion of growth factors. The present invention provides the advantage that aged stem cells can be expanded for a longer period of time and with a higher stem cell yield. Further, stem cell lines and tissue engineered construct drafts made or derived from cells reprogrammed by the present process show a reduced minimal immunological risk, in particular if the patient's own cells are used as a source for the reprogramming. Thus, the present invention provides means and methods to prepare in particular pluripotent stem cells, to provide multipotent stem cells, to provide means and methods for an increased expansion of cells or stem cells in vitro and for the rejuvenation of aged cells or aged stem cells for tissue engineering or cell therapies.

[0012] In particular, the present invention foresees, preferably in a first step, to provide cells to be reprogrammed. Preferably, the cells to be reprogrammed may be adult, neonatal or embryonic differentiated cells, but are not limited thereto. Preferably, the cells to be reprogrammed are adult or neonatal undifferentiated cells. All of these cells may, in a preferred embodiment, be cell lines, immortalized cells, cells kept in cell culture, isolated cell populations, preferably cells isolated from a donor, either a living or dead donor, or cells isolated from the environment. Cell types which can be reprogrammed according to the present invention potentially are all cell types, and are in preferred instances fibroblasts, hepatocytes, cardiac cells, cardiomyocytes, nerve cells, chondrocytes, osteoblasts, adipocytes, myoblasts, hepatoblasts, hepatic stem cells, insulin producing cells, neural stem cells, cardiomyogenic cells, dermatocytes, keratinocytes, pancreatic cells, monocytes, epithelial cells or mesenchymal stem cells (MSC). Preferably, the cells may be mammalian cells, in particular human cells or animal cells, preferably ovine, horse, ape or in particular rodent cells, preferably hamster cells, mouse cells or rat cells. The cells may also be fish, reptile, avian, amphibian or insect cells. Preferably, the cells to be reprogrammed are lineage-committed cells. In a further preferred embodiment the cells, in particular the cells of the above identified origin, are stem cells, in particular post-natal stem cells or non-embryonic stem cells.

[0013] A suitable and preferred stem cell source like mesenchymal stem cells is a tissue within the human or animal body which comprises the stem cells for use in the present invention, optionally together with other cell types. Preferably, the suitable stem cell source is bone marrow, both adult and fetal, cytokine or chemotherapy mobilized peripheral blood, fetal liver, umbilical cord blood, embryonic yolk sac and spleen, both adult and fetal, more preferably the stem cell source is adult bone marrow or umbilical cord blood, most preferably the stem cell source is bone marrow. Bone marrow cells may be obtained from any known source, including, but not limited to, ilium, sternum, tibiae, femora, spine or other bone cavities. Preferably, the stem cells are isolated from a mammalian organism such as human, mouse or rat, and more preferably the stem cells are isolated from a human organism.

[0014] The term "isolated cell population" is intended to mean that the cells are not in contact with other cells with which they are usually in contact within the body of the mammal or in a tissue sample obtained directly, i.e. without purification or enrichment step, from the mammal. A "cell population" according to the present invention may comprise not only cells of one cell type such as fibroblasts or mesenchymal stem cells as defined for example by the expression of a specific combination of surface markers, but also a mixture of cells of different cell types which show different combinations of surface markers.

[0015] The cells harvested from said sources may be used directly for transfection or may be cryoconserved by freezing them at a temperature from about - 196 °C to about - 130 °C.

[0016] The cells to be reprogrammed receive, according to the present invention, in a second step at least one species of reprogramming mRNA molecules, in particular linear and isolated mRNA molecules, selected from the group of mRNA molecules encoding Ronin, mRNA molecules encoding Oct4, mRNA molecules encoding Klf4, mRNA molecules encoding Sox2, mRNA molecules encoding Nanog and mRNA molecules encoding TERT. Ronin, Oct4, Klf4, Sox2, Nanog and TERT are proteins with the ability to reprogram cells. In the context of the present invention these proteins are termed "reprogramming proteins" and are characterised by their ability to reprogram target cells and therefore by their regulatory function in terms of determining the cell fate, in particular being able to dedifferentiate a target cell and/or maintain a cell in a dedifferentiated state, preferably by being transcription factors.

[0017] Differentiation behaviour of cells and state of differentiation can be detected according to the methods set forth below. However any method for determining the differentiation state or potency of a cell known to the skilled person is applicable as well.

[0018] In a preferred embodiment, the cell to be reprogrammed is transfected with one or more reprogramming mRNA molecules according to the present invention. In another preferred embodiment the cell to be reprogrammed is supplemented with one or more reprogramming mRNA molecules according to the present invention. In another preferred embodiment the cell to be reprogrammed is injected with one or more reprogramming mRNA molecules according to the present invention.

[0019] The present invention thus foresees to use one or more of mRNA molecules encoding Ronin, Oct4, Klf4, Sox2, Nanog or TERT. These mRNA molecules may, in a preferred embodiment, be molecules having the wild-type mammalian, in particular human, animal, preferably rodent, more preferably mouse, hamster or rat or any other animal nucleotide sequence. In a preferred embodiment of the present invention the reprogramming mRNA molecule is selected from the group consisting of mRNA nucleotide sequence molecules being encoded by any one of the DNA sequences given

under SEQ ID No. 1 to 16.

[0020] Of course, the invention also foresees to use mRNA molecules, whose sequence is a functional equivalent to the polynucleotide sequence given above. In the context of the present invention a functional equivalent is a nucleotide sequence molecule, which either codes with a different nucleotide sequence exactly the same protein as the mRNA sequence encoded by any one of SEQ ID No. 1 to 16 or is a mRNA sequence, which encodes a protein with a different amino acid sequence but with same or similar function, in particular being able to reprogram the cells according to the present invention.

[0021] In a particularly preferred embodiment of the present invention the functional equivalent of the mRNA molecules is a polynucleotide with a homologous sequence to the wild-type mRNA polynucleotide as encoded by the DNA sequence in any one of SEQ ID No. 1 to 16. In a preferred embodiment of the present invention the degree or percentage of homology is at least 50, 60, 70, 80, 90, 95, 99 or 100%. In a furthermore preferred embodiment a functional equivalent of the mRNA molecules as given in any one of SEQ ID No. 1 to 16 is a mRNA sequence which is encoded by a DNA sequence being substantially complementary to the sequences of any one of SEQ ID No. 1 to 16 or to its complementary, preferably substantially, complementary sequence. In a furthermore preferred embodiment the functional equivalent of the mRNA molecule as encoded by any one of the DNA sequences of SEQ ID No. 1 to 16 is a mRNA molecule being encoded by a DNA sequence which is able to hybridize under stringent or reduced stringent conditions to any one of the polynucleotides given in SEQ ID No. 1 to 16 or to its complementary, preferably substantially, complementary sequence.

[0022] In the context of the present invention the term "mRNA molecule" is meant to refer to a linear polymer of ribonucleotide molecules, which is single-stranded and serves as a template for protein synthesis.

[0023] Polynucleotides have "homologous" sequences if the sequence of nucleotides in the two sequences is the same when aligned for maximum correspondence as described herein. Sequence comparison between two or more polynucleotides is generally performed by comparing portions of the two sequences over a comparison window to identify and compare local regions of sequence similarity. The comparison window is generally from about 20 to 200 contiguous nucleotides.

[0024] The "percentage of sequence homology" for polynucleotides, herein referred to be 50, 60, 70, 80, 90, 95, 98, 99 or 100 percent sequence homology, may be determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may include additions or deletions (i.e. gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by: (a) determining the number of positions at which the identical nucleic acid base occurs in both sequences to yield the number of matched positions; (b) dividing the number of matched positions by the total number of positions in the window of comparison; and (c) multiplying the result by 100 to yield the percentage of sequence homology. Optimal alignment of sequences for comparison may be conducted by computerized implementations of known algorithms, or by inspection. Readily available sequence comparison and multiple sequence alignment algorithms are, respectively, the Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. 1990. J. Mol. Biol. 215:403; Altschul, S.F. et al. 1997. Nucleic Acid Res. 25:3389-3402) and ClustalW programs both available on the internet. Other suitable programs include GAP, BESTFIT and FASTA in the Wisconsin Genetics Software Package (Genetics Computer Group (GCG), Madison, WI, USA).

[0025] As used herein, "substantially complementary" means that two nucleic acid sequences in question have at least about 65%, preferably about 70%, more preferably about 80%, even more preferably 90%, and most preferably about 98%, sequence complementarity to each other. This means that the DNA sequence coding the functional equivalent and the polynucleotide given in any of SEQ ID No. 1 to 16 or its complement must in a preferred embodiment exhibit sufficient complementarity to hybridise under stringent conditions. A substantially complementary sequence is preferably one that has sufficient sequence complementarity to the nucleotide sequence in question to result in binding.

[0026] The term "primer" as used herein refers to an oligonucleotide which is capable of annealing to the amplification target allowing a DNA polymerase to attach thereby serving as a point of initiation of DNA synthesis when placed under conditions in which synthesis of primer extension product which is complementary to a nucleic acid strand is induced, i.e., in the presence of nucleotides and an agent for polymerization such as DNA polymerase and at a suitable temperature and pH. The (amplification) primer is preferably single stranded for maximum efficiency in amplification. Preferably, the primer is an oligodeoxy ribonucleotide. The primer must be sufficiently long to prime the synthesis of extension products in the presence of the agent for polymerization. The exact lengths of the primers will depend on many factors, including temperature and source of primer.

[0027] A "pair of bi-directional primers" as used herein refers to one forward and one reverse primer as commonly used in the art of DNA amplification such as in PCR amplification.

[0028] The terms "stringency" or "stringent hybridization conditions" refer to hybridization conditions that affect the stability of hybrids, e.g., temperature, salt concentration, pH, formamide concentration and the like. These conditions are empirically optimised to maximize specific binding and minimize nonspecific binding of an oligo- or polynucleotide to its target nucleic acid sequence. The terms as used include reference to conditions under which an oligo- or polynu-

cleotide will hybridise to its target sequence, to a detectably greater degree than other sequences (e.g. at least 2-fold over background). Stringent conditions are sequence dependent and will be different in different circumstances. Longer sequences hybridise specifically at higher temperatures.

[0029] Generally, stringent conditions are selected to be about 5 DEG C (degree celcius) lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of a complementary target sequence hybridises to a perfectly matched oligo- or polynucleotide. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M Na \leftrightarrow ion, typically about 0.01 to 1.0 M Na \leftrightarrow ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30 DEG C for short probes or primers (e.g. 10 to 50 nucleotides) and at least about 60 DEG C for long probes or primers (e.g. greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide.

[0030] Exemplary low stringent conditions or "conditions of reduced stringency" include hybridization with a buffer solution of 30% formamide, 1 M NaCl, 1% SDS at 37 DEG C and a wash in 2x SSC at 40 DEG C. Exemplary high stringency conditions include hybridization in 50% formamide, 1 M NaCl, 1% SDS at 37 DEG C, and a wash in 0.1x SSC at 60 DEG C. Hybridization procedures are well known in the art and are described in e.g. Ausubel et al, Current Protocols in Molecular Biology, John Wiley & Sons Inc., 1994.

[0031] Thus, the present invention foresees to introduce, preferably transfect, specific reprogramming mRNA molecules into the cells, which mRNA molecules once introduced, preferably transfected, in the cells are able to be translated into so called reprogramming proteins which can turn on specific genes in the cells, in particular multipotency and/or the pluripotency genes in the cell. The mRNA molecule used according to the present invention is preferably a linear molecule having a poly A tail, most preferably produced by in vitro transcription. Thus, in a preferred embodiment the mRNA molecules are produced by in vitro transcription, in particular using bacterial systems. In a particular preferred embodiment the DNA sequences of the reprogramming proteins are cloned into plasmids and amplified in bacteria, for instance E. coli. In a further preferred embodiment, the plasmids are then isolated from the bacteria, are linearised and subjected to restriction digestion. In a further preferred embodiment cDNA prepared by said method is transcribed into mRNA, which in turn is incubated to destroy cDNA residues and to obtain mRNA molecules to be introduced into the cells.

[0032] Since the introduced reprogramming mRNA molecules and the proteins translated therefrom are over the time being degraded in the cells, they cannot permanently integrate into the genome of the cell providing some of the advantageous features of the present invention.

[0033] In a preferred embodiment of the present invention the present teaching foresees to introduce, preferably transfect, the reprogramming mRNA molecules into the cell by electroporation, by lipofection, by injection, by magnetofection, by particle bombardment, gene gun, or by any other method known in the art suitable to introduce mRNA molecules into a target cell.

[0034] In a particular preferred embodiment the present invention further foresees in its step c) to culture the cells into which the reprogramming mRNA molecules have been introduced in a cell culture medium and under a condition suitable to allow translation of the transfecting reprogramming mRNA molecules, so as to obtain the reprogrammed cells.

[0035] In a particularly preferred embodiment of the present invention the present process therefore consists of the above-identified steps a), b) and c), preferably in this order. Accordingly, the present invention excludes any further process steps, in particular any further substantial process step, in particular any intervening or subsequent process steps. Thus, the present invention provides its advantages in a simple and cost-effective way.

[0036] In a particularly preferred embodiment the cell culture system is a cell culture system, comprising a cell culture medium, preferably in a culture vessel, in particular a cell culture medium supplemented with at least one so called "inducing substance", which is a substance suitable and determined for protecting the cells from in vitro aging and/or inducing in an unspecific or specific reprogramming. In a particularly preferred embodiment an inducing substance according to the present invention is a substance selected from the group consisting of reversin, resveratrol, selenium, a selenium-containing compound, EGCG ((-)-epigallocatechin-3-gallate), valporic acid and salts of valporic acid, in particular sodium valporate.

[0037] In a particularly preferred embodiment the at least one inducing substance is present in the cell culture medium used in step c) of the present process in a concentration from 0.001 to 100 μ M, preferably from 0.005 to 50 μ M.

[0038] In a particularly preferred embodiment the present invention foresees to use a concentration of reversin from 0.5 to 10 μ M, preferably of 1 μ M. In a furthermore preferred embodiment the present invention foresees to use resveratrol in a concentration of 10 to 100 μ M, preferably 50 μ M. In a furthermore preferred embodiment the present invention foresees to use selenium or a selenium containing compound in a concentration from 0.05 to 0.5 μ M, preferably of 0.1 μ M. In a furthermore preferred embodiment the present invention foresees to use EGCG in a concentration from 0.001 to 0.1 μ M, preferably of 0.01 μ M. In a furthermore preferred embodiment the present invention foresees to use valporic acid or sodium valporate in a concentration from 1 to 10 μ M, in particular of 5 μ M.

[0039] The present invention foresees in a furthermore preferred embodiment culturing the cells obtained in step b) in a cell culture medium, wherein the cell culture medium comprises, optionally in combination with the inducing substance

as specified above, at least one transient proteolysis inhibitor. The use of at least one proteolysis inhibitor in the cell culture medium of the present invention increases the time the reprogramming proteins derived from the mRNA or any endogenous genes will be present in the cells and thus facilitates in an even more improved way the reprogramming by the transfected mRNA derived factors. The present invention uses in a particularly preferred embodiment as a transient

proteolysis inhibitor a protease inhibitor, a proteasome inhibitor and/or a lysosome inhibitor. In a particularly preferred embodiment the proteasome inhibitor is selected from the group consisting of MG132, TMC-95A, TS-341 and MG262.

[0040] In a furthermore preferred embodiment the protease inhibitor is selected from the group consisting of aprotinin, G-64 and leupeptine-hemisulfat. In a furthermore preferred embodiment the lysosomal inhibitor is ammonium chloride.

[0041] In a furthermore preferred embodiment the present invention also foresees a cell culture medium comprising

at least one transient inhibitor of mRNA degradation. The use of a transient inhibitor of mRNA degradation increases the half-life of the reprogramming factors as well.

[0042] In a furthermore preferred embodiment of the present invention a condition suitable to allow translation of the transfected reprogramming mRNA molecules in the cells is an oxygen content in the cell culture medium from 0.5 to 21 %, preferably from 1 to 20%, more preferably from 5 to 19% and particularly preferred from 10 to 18%. More particular,

and without wishing to be bound to theory, oxygen is used to further induce or increase Oct4 by triggering Oct4 via Hif1a.

[0043] In a preferred embodiment conditions that are suitable to support reprogramming of the cells by the mRNA molecules in the cells are selected; more particularly, these conditions require a temperature from 30 to 38°C, preferably from 31 to 37°C, most preferably from 32 to 36°C.

[0044] The glucose content of the medium is in a preferred embodiment of the present invention below 4.6 g/l, preferably below 4.5 g/l, more preferably below 4 g/l, even more preferably below 3 g/l, particularly preferably below 2 g/l and most preferably it is 1 g/l. DMEM media containing 1 g/l glucose being preferred for the present invention are commercially available as "DMEM low glucose" from companies such as PAA, Omega Scientific, Perbio and Biosera. More particular, and without wishing to be bound to the theory, high glucose conditions adversely support aging of cells (methylation, epigenetics) in vitro which may render the reprogramming difficult.

[0045] In a furthermore preferred embodiment of the present invention the cell culture medium contains glucose in a concentration from 0.1 g/l to 4.6 g/l, preferably from 0.5 g/l to 4,5 g/l and most preferably from 1 g/l to 4 g/l.

[0046] The terms "cell culture" and "culturing of cells" refer to the maintenance and propagation of cells and preferably human, human-derived and animal cells in vitro.

[0047] "Cell culture medium" is used for the maintenance of cells in culture in vitro. For some cell types, the medium may also be sufficient to support the proliferation of the cells in culture. A medium according to the present invention provides nutrients such as energy sources, amino acids and anorganic ions. Additionally, it may contain a dye like phenol red, sodium pyruvate, several vitamins, free fatty acids, antibiotics, anti-oxidants and trace elements.

[0048] For culturing the stem cells according to the present invention any standard medium such as Iscove's Modified Dulbecco's Media (IMDM), alpha-MEM, Dulbecco's Modified Eagle Media (DMEM), RPMI Media and McCoy's Medium is suitable before reprogramming. Once the cells have been reprogrammed, they can in a preferred embodiment be cultured in embryonic stem cell medium.

[0049] Preferably, the medium additionally comprises one or more additives selected from the group consisting of vitamin D3 (1,25-dihydroxyvitamin D3, calcitriol), resveratrol (trans-3, 4', 5-trihydroxystilbene), reversine (2-(4-morpholinoanilino)- N6-cyclohexyladenine), vitamin E (RRR- α -tocopherol), valproic acid (dekapene, valproate, valrelease), EGCG (epigallocatechin-3-gallat) and selenium. Preferably, two of the afore-mentioned additives are present, more preferably three of the afore-mentioned additives are present, even more preferably four of the afore-mentioned additives are present, particularly preferably five of the afore-mentioned additives are present and most preferably all of the aforementioned additives are present.

[0050] These media are well-known to a person skilled in the art and may be purchased from companies such as Cambrex, Invitrogen, Sigma-Aldrich or Stem Cell Technologies.

[0051] The medium may in a particular embodiment further comprise a serum component such as horse serum, human serum or fetal calf serum (FCS). Preferably, the medium contains FCS. If present, the serum is present in a concentration of 1 -20%, preferably of 3-18%, more preferably of 5-15%, even more preferably of 8-12% and most preferably of 10%. Alternatively the serum component may be replaced by any of several standard serum replacement mixtures which typically include insulin, albumin and lecithin or cholesterol.

[0052] A "culture vessel" is any vessel which is suitable for growing cells in a culture medium, in particular selected from, but not limited to, agar, matrigel and collagen, either in fluid phase or adhered to an interior surface of the container. Types of such specialized vessels include roller bottles, spinner flasks, petri dishes and tissue flasks. Culture vessels are designed to be incubated in temperature, humidity and gas controlled environments to facilitate maximum cell or tissue growth. Generally, a layer of cell culture medium or agar covers the growing surface. The portion of the vessel not utilized as a growing surface encloses the interior gaseous environment which surrounds the cell culture. Cells, tissues, microorganisms and the like typically are introduced into the interior of cell culture vessels through an opening in the vessel. After introduction of the cells the opening may be closed such that the cells are not in contact with the

environment during the culturing of the cells.

[0053] In a preferred embodiment of the present invention, the culture vessel is treated for tissue culture, which means that the surface of the culture vessel is treated such that cells which usually grow in an adherent state grow adherently, but cells which grow in suspension do not adhere or adhere only loosely. Such treatment may involve the irradiation of the vessel or the coating of the vessel, for example with a special plastic, polymer or nanostructure or with proteins of the extracellular matrix. Such vessels can comprise tissue culture dishes and tissue culture flasks and are available from different suppliers such as Becton Dickinson, Greiner, Sigma and TPP.

[0054] The present invention also relates to a process for the production of cells exhibiting a multipotent, preferably a multipotent, stem cell character, wherein a process according to the above is carried out.

[0055] The present invention also relates to a process for improving the expansion of stem cells in vitro, wherein a process according to the present invention is carried out. Thus, the present invention provides the advantage of prolonging expansion of stem cells, since the present invention keeps the cells to be expanded in a dedifferentiated status.

[0056] The present invention also relates to a process for the rejuvenation of aged cells, wherein a process according to the present invention is carried out.

[0057] The present invention also relates to a process for inducing the dedifferentiation of cells, wherein a process according to the present invention is carried out and wherein in particular the cells to be reprogrammed are differentiated cells, in particular lineage-committed cells.

[0058] The present invention also relates to a process for reprogramming recipient cells of a mammal in vivo comprising introducing reprogramming mRNA molecules into the recipient cells of the mammal wherein the reprogramming mRNA molecules are encoding at least one reprogramming protein selected from the group consisting of Ronin, Oct4, Klf4, Sox2, Nanog and TERT. Thus, the present invention also relates to an in vivo method for reprogramming recipient cells of a mammal which employ the reprogramming mRNA molecules as identified above for the in vitro embodiment of the present invention. The present invention relating to the process for reprogramming recipient cells of a mammal in vivo thereby foresees to introduce the reprogramming mRNA molecules directly into at least one cell of a recipient mammal that means into at least one recipient cell by suitable means such as gene gun insertion. Such a process allows the production of a mammal in particular a human being which has at least one reprogrammed cell. Thus, this embodiment of the present invention provides terrifically improved therapeutic application, in particular in the regenerative medicine and/or in replacement therapy. Thus, the present invention relates to a method of treating a mammal, in particular human being wherein reprogramming mRNA molecules are introduced into at least one cell of the recipient mammal and wherein the reprogrammed mRNA molecules are encoded at least by encoding at least one reprogramming protein selected from the group consisting of Ronin, Oct4, Klf4, Sox2, Nanog and TERT.

[0059] The present invention also relates to a multipotent, in particular a pluripotent, stem cell prepared according to any one of the methods of the present invention. Thus, the reprogrammed cells according to the present invention are preferably multipotent, in particular pluripotent stem cells. In a preferred embodiment the cells obtained according to the present invention are distinguished from the cells used as a starting material in step a) of the present invention by lack of one or more markers. These cells may in a preferred embodiment be also characterized by a particular methylation pattern, by the expression of oct4, sox2, nanog, hTERT or klf4. expression of oct4, which is not found in somatic cells like fibroblasts, becomes expressed after transfecting mRNA (klf4, sox2 and oct4) in human fibroblasts, by improved growth potential; and by increased differentiation potential. For pluripotency the formation of embryoid bodies, production of cells of all three germ layers in vitro and in vivo. Examples thereof are illustrated in the accompanying figures and example.

[0060] The reprogrammed cells obtained by the present process may preferably be characterized by the expression or non-expression of certain surface markers. These surface markers are usually given a cluster of differentiation (CD) designation which describes groups of immunophenotypical surface characteristics of cells. Usually CD molecules are membrane-bound glycoproteins which are recognized by a cluster of monoclonal antibodies that display the same cellular reactivity. These surface molecules may for example be detected by means of a flow cytometer such as a fluorescence-activated cell sorter (FACS) manufactured by companies such as Becton Dickinson. Methods to identify cells according to the present invention are methods to detect cell-specific proteins, methods to detect cell-specific transcription factors or methods to detect physiological or morphological changes. All of these methods are per se well-known in the prior art. In particular, these methods use well-known protein or DNA or RNA detection processes and/or the reporter gene assays. Of course, immunoassays or assays using fluorescently or radioactively labelled proteins or nucleic acids including methods to measure enzymatic activities can be employed. Methods to detect morphological changes may include staining methods, visually based methods or the like.

[0061] Reprogrammed cells according to the present invention may be used for therapeutic, diagnostic or scientific purposes. In particular, these cells may be used in regenerative medicine and/or for replacement therapy.

[0062] The term "cell" not only refers to a single cell but also encompasses a cell line, a cell population or a cell clone.

[0063] The term "stem cells" refers to cells which have retained the capacity to proliferate and differentiate into one or different cell types. Stem cells created in accordance with the present invention are preferably pluripotent stem cells,

i.e. stem cells which have retained the capacity to differentiate into distinct cell lineages and cell types or multipotent stem cells, retaining a more restricted differentiation potential.

[0064] It is understood that the term "stem cells" in accordance with the invention does not comprise human embryos. Furthermore, it is understood that the term "stem cells" does not comprise pluripotent stem cells which have been directly derived from a human embryo. Embryonic stem cells which have been derived from publicly available and previously established stem cell lines are understood to fall within the meaning of the term "stem cells" as used by the present invention.

[0065] A "stem cell", as used herein, refers to any self-renewing pluripotent cell or multipotent cell or progenitor cell or precursor cell that is capable of differentiating into one or multiple cell types. Stem cells are thus cells able to differentiate into one or more than one cell type and have preferably an unlimited growth potential. Stem cells include those that are capable of differentiating into cells of osteoblast lineage, a mesenchymal cell lineage (e. g. bone, cartilage, adipose, muscle, stroma, including hematopoietic supportive stroma, and tendon). "Differentiate" or "differentiation", as used herein, refers to the process by which precursor or progenitor cells (i. e., stem cells) differentiate into specific cell types, e. g., osteoblasts. Differentiated cells can be identified by their patterns of gene expression and cell surface protein expression. "Dedifferentiate" or "dedifferentiation", as used herein, refers to the process by which lineage-committed cells (e. g., myoblasts or osteoblasts) reverse their lineage commitment and become precursor or progenitor cells (i. e., multipotent or pluripotent stem cells). Dedifferentiated cells can for instance be identified by loss of patterns of gene expression and cell surface protein expression associated with the lineage committed cells.

[0066] A "lineage-committed cell" as used herein, refers to any cell that has or will differentiate into a particular cell type or related cell types. Lineage committed cells include, for example, osteoblasts, myoblasts, chondrocytes, and adipocytes.

[0067] Totipotent stem cells are able to create all cell types of the body, including placental cells. The earlier stage foetal stem cells are considered totipotent, as well as the fertilised egg. They also have the ability to replicate in unlimited numbers without losing their potential.

[0068] Pluripotent stem cells are able to create cells of all three germ layer, namely the ecto-, endo- and mesoderm. They also have the ability to replicate in unlimited numbers without losing their potential.

[0069] Multipotent stem cells are able to produce cells of one or more germ layers or several types of tissues. They often have an already limited self-renewal ability.

[0070] Stem cells are thus cells able to differentiate into one or more than one cell type and have preferably an unlimited growth potential.

[0071] Progenitor cells can differentiate into one or more cell types but have a limited growth potential.

[0072] Adult stem cells are stem cells derived from an adult organism and might be multipotent or pluripotent.

[0073] Embryonic stem cells are derived from the inner mass of a blastula and are pluripotent. Embryonic stem cells are unique because they can develop into nearly all cell types, an attribute called pluripotency. But to access these cells, researchers must destroy a viable embryo. In this patent we are describing a way to create cells, with the characteristics of embryonic stem cells, without the need to destroy embryos or the use of embryonic stem cells.

[0074] Induced pluripotent stem cells "IPS" cells are pluripotent stem cells artificially derived from non-pluripotent cells, including somatic cells, adult multipotent stem cells or progenitor cells. In principal every cell containing a nuclei can be used as source for IPS cells.

[0075] Further preferred embodiments of the present invention are the subject matter of the subclaims.

[0076] The sequence listing show the prior art DNA sequences encoding the mRNA nucleotide sequence molecules used in the present invention:

Table 1

SEQ ID No.	gene	accession-number	length
1	hNanog	NM_024865	2098
2	mNanog	NM_028016	1356
3	rNanog	NM_001100781	2358
4	hSox2	NM_003106	2518
5	mSox2	NM_011443	2457
6	rSox2	NM_001109181	2323
7	hOct4	NM_002701	1411
8	mOct4	NM_013633	1346

(continued)

SEQ ID No.	gene	accession-number	length
9	hKlf4	NM_004235	2949
10	mKlf4	NM_010637	3057
11	rKlf4	NM_053713	2393
12	hTERT	NM_198253	4018
13	mTert	ENSMUSG00000021611	4237
14	rTERT	NM_053423	3378
15	hRonin	NM_020457	1903
16	mRonin	NM_021513	1832
abbreviations: h = human; m = mouse; r = rat			

[0077] The designations marked "NM" and ENSMUSG refer to the NM(NCBI)- and ENSMUSG-accession numbers as given under the publically available website <http://www.ncbi.nlm.nih.gov> and <http://www.ensembl.org>.

[0078] SEQ ID No. 17 and 18 show the DNA sequence of primers used for cloning the human Nanog gene.

[0079] SEQ ID No. 19 and 20 show the DNA sequence of primers used for cloning the human Klf4 gene.

[0080] SEQ ID No. 21 and 22 show the DNA sequence of primers used for cloning the human Sox2 gene.

[0081] SEQ ID No. 23 and 24 show the DNA sequence of primers used for cloning the human Oct4 gene.

[0082] SEQ ID No. 25 and 26 show the DNA sequence of primers used for cloning the human Tert gene.

[0083] SEQ ID No. 27 and 28 show the DNA sequence of primers used for cloning the GFP gene.

[0084] The present invention will now be illustrated in more detail by way of an example and figures.

[0085] The figures show:

Figure 1: Promotor methylation of rex1, nanog and oct4 in human fibroblasts before and after reprogramming (Figure 1A: Rex; Figure 1AB: Nanog; Figure 1C: Oct4). CpG island are represented as squares. Black squares represent methylated and white squares represent unmethylated CpG islands. All samples are primary fibroblasts from a young male donor.

Figure 2: Fluorescence and morphology after amaxa elektroporation (klf4, sox2, oct4): Human primary fibroblasts were transfected with 0,6 $\mu\text{g}/\mu\text{l}$ mRNA per factor and 0,2 $\mu\text{g}/\mu\text{l}$ GFP mRNA to visualize the transfection efficiency. Top line are fluorescence pictures and the bottom line shows the morphology of the cells after 2 days.

Figure 3: Fluorescence and morphology after Fugene transfection (klf4, sox2, oct4): Human primary fibroblasts were transfected with 0,6 $\mu\text{g}/\mu\text{l}$ mRNA per factor and 0,2 $\mu\text{g}/\mu\text{l}$ GFP mRNA to visualize the transfection efficiency. Top line are fluorescence pictures and the bottom line shows the morphology of the cells after 7 days.

Figure 4: RT-PCR for Oct4: L: 20 bp Ladder (Fermentas); 1 hOct4 hypoxia factors 1x transfected; 2: hOct4 hypoxia factors 6x transfected; 3: hOct4 hypoxia factors 6x transfected +Cock; 4: hOct4 normoxia factors 1x transfected; 5: hOct4 normoxia factors 6x transfected; 6: hOct4 normoxia factors 6x transfected +Cock; 7: hOct4 normoxia factors 6x transfected +Cock+MG-132; 1 a: hOct4 RNA after DNase digestion; 2a: hOct4 RNA after DNase digestion; 3 a: hOct4 RNA after DNase digestion; 4a: hOct4 RNA after DNase digestion; 5a: hOct4 RNA after DNase digestion; 6a: hOct4 RNA after DNase digestion; 7a: hOct4 RNA after DNase digestion; 8: Oct4 negative control.

Figure 5: RT-PCR for hOct4: L: 20 bp Ladder (Fermentas); 1 : hOct4 hypoxia factors 1x transfected (human fibroblasts); 2: hOct4 hypoxia factors 6x transfected (human fibroblasts mit mRNA transfected); 3: hOct4 hypoxia factors 6x transfected +Cocktail (human fibroblasts transfected with mRNA and chemical reprogramming cocktail); 4: hOct normoxia factors 1x transfected; 5: hOct4 normoxia factors 6x transfected; 6: hOct4 normoxia factors 6x transfected + cocktail, 7: hOct4 normoxia 6x transfected factors + cocktail + MG-132; 8: hOct4 positive control (plasmid with hKlf4), 9: hOct4 negative control (water).

Figure 6: RT-PCR for hOct4 and GAPDH: 1 hOct4 hypoxia factors 1x transfected; 2 hOct4 hypoxia factors 6x transfected; 3 hOct4 hypoxia factors 6x transfected +chemical cocktail; 4 hOct4 normoxia factors 1x transfected; 5 hOct4

normoxy factors 6x transfected; 6 hOct4 normoxy factors 6x transfected + chemical cocktail; 7 hOct4 normoxy factors 6x transfected + chemical cocktail + MG-132; 1 a hOct4 RNA after DNase digestion; 2a hOct4 RNA after DNase digestion; 3a hOct4 RNA after DNase digestion; 4a hOct4 RNA after DNase digestion; 5a hOct4 RNA after DNase digestion; 6a hOct4 RNA after DNase digestion; 7a hOct4 RNA after DNase digestion; 8a Oct4 negative control; 1 b GAPDH hypoxia factors 1x transfected; 2b GAPDH hypoxia factors 6x transfected; 3b GAPDH hypoxia factors 6x transfected + chemical cocktail; 4b GAPDH normoxy factors 1x transfected; 5b GAPDH normoxy factors 6x transfected; 6b GAPDH normoxy factors 6x transfected + chemical cocktail; 7b GAPDH normoxy factors 6x transfected + chemical cocktail + MG-132; 8b GAPDH negative control.

Figure 7: RT-PCR for hKlf4 and hNanog: L: 20 bp Ladder (Fermentas); 1a: hKlf4 hypoxia factors 1x transfected (human fibroblasts); 2a: hKlf4 hypoxia factors 6x transfected (human fibroblasts with transfected mRNA); 3 a: hKlf4 hypoxia factors 6x transfected + cocktail (human fibroblasts transfected with mRNA + chemical reprogramming cocktail); 4a: hKlf4 normoxy factors 1x transfected; 5a: hKlf4 normoxy factors 6x transfected; 6a: hKlf4 normoxy factors 6x transfected + cocktail, 7a: hKlf4 normoxy 6x transfected factors + cocktail + MG-132; 8a: hKlf4 pos. control (plasmid with hKlf4), 9a: hKlf4 neg. control (water) 1b: hNanog hypoxia factors 1x transfected (human fibroblasts); 2b: hNanog hypoxia factors 6x transfected (human fibroblasts mit mRNA transfected); 3b: hNanog hypoxia factors 6x transfected + cocktail (human fibroblasts transfected with mRNA + chemical reprogramming cocktail); 4b: hNanog normoxy factors 1x transfected; 5b: hNanog normoxy factors 6x transfected; 6b: hNanog normoxy factors 6x transfected + cocktail, 7b: hNanog normoxy 6x transfected factors + cocktail + MG-132; 8b hNanog pos. control (plasmid with hNanog), 10 hNanog neg. control (water).

Figure 8: Results from RNA BioAnalyzer Analysis (Agilent Nano Chip; Agilent Technologies) for oct4, sox2, and klf4:

[0086] Further preferred embodiments of the invention are reflected by the below consecutively numbered sentences:

1. A process for preparing reprogrammed cells in vitro, comprising

- a) providing cells to be reprogrammed,
- b) introducing reprogramming mRNA molecules into the cells provided in step a), wherein the reprogramming mRNA molecules are encoding at least one reprogramming protein selected from the group consisting of Ronin, Oct4, Klf4, Sox2, Nanog and TERT,
- c) culturing the cells obtained in step b) in a cell culture medium and under a condition suitable to allow translation of the transfected reprogramming mRNA molecules so as to obtain reprogrammed cells.

2. The process according to embodiment 1, wherein the condition suitable to allow translation is an oxygen content in the cell culture medium from 0.5 % to 21 %.

3. The process according to embodiments 1 or 2, wherein the condition suitable to allow translation is a temperature from 30°C to 38°C.

4. The process according to any one of the preceding embodiments, wherein the cell culture medium has a glucose content of 0.1 g/l to 4.6 g/l.

5. The process according to any one of the preceding embodiments, wherein the cell culture medium contains at least one inducing substance selected from the group consisting of reversin, resveratrol, selenium, selenium containing compounds, EGCG ((-)-epigallocatechin-3-gallate), valporic acid, salts of valporic acid and sodium valproate.

6. The process according to any one of embodiments 1 to 5, wherein the cell culture medium contains at least one transient proteolysis inhibitor.

7. The process according to embodiment 6, wherein the transient proteolysis inhibitor is selected from the group consisting of protease inhibitor, proteasome inhibitor and lysosome inhibitor.

8. The process according to any one of the preceding embodiments, wherein the cells to be reprogrammed are human cells.

9. The process according to any one of the preceding embodiments, wherein the cells to be reprogrammed are non-embryonic stem cells.

10. A process for the production of cells exhibiting a pluripotent or multipotent stem cell character, wherein a process according to any one of embodiments 1 to 9 is carried out.

11. A process for inducing the dedifferentiation of cells, wherein a process according to any one of embodiments 1 to 9 is carried out.

12. A process for improving the expansion of non-embryonic stem cells in vitro, wherein a process according to any one of embodiments 1 to 9 is carried out.

13. A process for the rejuvenation of aged cells, wherein a process according to any one of embodiments 1 to 9 is carried out.

14. A multipotent or pluripotent stem cell prepared according to any one of the methods of embodiments 1 to 10.

15. A process for reprogramming recipient cells of a mammal in vivo comprising introducing reprogramming mRNA molecules into the recipient cells of the mammal wherein the reprogramming mRNA molecules are encoding at least one reprogramming protein selected from the group consisting of Ronin, Oct4, Klf4, Sox2, Nanog and TERT.

Example

1. Preparation of reprogramming mRNA

1. A) Preparation of mRNA expression plasmids

[0087] For the construction of plasmids comprising the target genes in a vector with the T7-promoter for in *vitro* transcription, using PCR, digest sites before the start-codon and after the stop codon were designed for direct cloning of the gene inserts (see Table 1) in the right direction into the pCR@II-Vector (Invitrogen).

[0088] The primers used are listed in Table 2.

Table 2

Name gen	New digest sites for restriction enzymes	Primer sequence 5'-3'	Product size
Nanog_human	XbaI & NotI	SEQ ID No. 17	918 bp
Nanog_human	SpeI & ClaI	SEQ ID No. 18	
Klf4_human	XbaI & NotI	SEQ ID No. 19	637 bp
Klf4_human	HindIII & ClaI	SEQ ID No. 20	
Sox2_human	XbaI & BamHI	SEQ ID No. 21	996 bp
Sox2_human	HindIII & ClaI	SEQ ID No. 22	
Oct4_human	XbaI & NotI	SEQ ID No. 23	1100 bp
Oct4_human	BamHI & ClaI	SEQ ID No. 24	
Tert_human	XbaI & NotI	SEQ ID No. 25	783 bp
Tert_human	HindIII & ClaI	SEQ ID No. 26	
GFP	XbaI & NotI	SEQ ID No. 27	724 bp
GFP	HindIII & ClaI	SEQ ID No. 28	

[0089] A PCR for obtaining the desired digest sites was carried out with the Platinum Taq-Polymerase (Invitrogen).

Preparation of PCR-reaction on ice:

[0090]

5 µl 10x PCR Buffer

EP 2 881 461 A1

(continued)

1 µl	10 mM dNTP mixture 0.2 mM each
1.5 µl	50 mM MgCl ₂
1 µl	Primer mix (10 µM each) 0.2 µM each
1 µl	Template DNA
0.2 µl	Platinum® Taq DNA Polymerase 1.0 unit
to 50 µl	DEPC-H ₂ O

PCR-Program (Biometra Tprofessional):

[0091]

95°C	2 min
95°C	30 sec
60°C	30 sec
70°C	30 sec
70°C	10 min
4°C	for ever

←
35 x

[0092] After electrophoresis in a 1 % TAE-agarose-gel, specific DNA-bands (for their size see Table 2) were cut out and the DNA extracted and purified with the QIAquick Gel Extraction Kit (from Qiagen)

Procedure:

[0093]

- excise the DNA fragment from the agarose gel with a scalpel
- weigh the gel slice
- add 3 volumes of Buffer QG to 1 volume of gel (For example, add 300 µl of Buffer QG to each 100 mg of gel)
- incubate at 50°C for 10 min (or until the gel slice has completely dissolved)
- add 1 gel volume of isopropanol to the sample and mix
- place a QIAquick spin column in a provided 2 ml collection tube
- to bind DNA, apply the sample to the QIAquick column, and centrifuge for 1 min at 13,000 rpm
- discard flow-through
- add 0.5 ml of Buffer QG to QIAquick column and centrifuge for 1 min at 13,000 rpm
- to wash, add 0.75 ml of Buffer PE to QIAquick column and centrifuge for 1 min at 13,000 rpm
- discard the flow-through
- centrifuge the QIAquick column for an additional 1 min at 13,000 rpm
- place QIAquick column into a 1.5 ml micro centrifuge tube
- to elute DNA, add 50 µl of H₂O to the centre of the QIAquick membrane, let the column stand for 1 min, and then centrifuge for 1 min at 13,000 rpm

[0094] Digest of pCRII-Vector with the specific restriction enzymes for cloning of target-DNA

Strategy for digest of vector pCRII:

[0095]

vector pCRII digest with XbaI and SpeI for target gene human Nanog
vector pCRII digest with XbaI and HindIII for target gene human Klf4
vector pCRII digest with XbaI and BamHI for target gene human Sox2

EP 2 881 461 A1

vector pCRII digest with XbaI and BamHI for target gene human Oct4
vector pCRII digest with XbaI and HindIII for target gene human TERT
vector pCRII digest with XbaI and HindIII for target gene GFP

5 Preparation of digest on ice:

[0096]

- 5 µl 10x Buffer
- 10 - ≥ 2 µg plasmid
- 2 µl restriction enzyme
- to 50 µl DEPC-water

- incubation for 1 h at 37°C (thermo block; Eppendorf)
- 15 - heat inactivation for 20 min by the specific temperature of the enzyme

[0097] Ligation of the target-gene inserts DNA with the linear vector DNA with the T4-DNA-Ligase (Fermentas)

Preparation of the ligation on ice:

20

[0098]

- 50-400 ng vector DNA
- 50-400 ng insert DNA
- 25 - 2 µl 10x Buffer
- 0.2 µl (1U) T4-DNA Ligase
- to 20 µl DEPC-water

- vortex the tube and spin down in a micro centrifuge for 3-5 seconds
- 30 - incubate on room temperature for 1 h
- heat inactivation for 20 min

1. B) Transformation of the plasmids with chemical competent DH5 α -bacteria

35 [0099]

- add 1 µl of the plasmids to 10 µl chemical competent DH5 α -bacteria
- incubation for 30 min on ice
- heat shock at 42°C for 45 sec
- 40 - add 250 µl SOC-Medium to the bacteria
- incubation at 37°C for 1h with shaking
- plate out the bacteria solution on LB-kanamycin-agarose-plate and incubate the plate for 12 hours in 37°C incubator
- pick one colony of the bacteria and put the colony in 5 ml LB-medium and incubate the solution for 12 hours in a bacteria incubator with shaking

45

1. C) Plasmid DNA purification with the NucleoSpin® Plasmid -KIT (Machery&Nagel)

[0100]

- 50 - 5 ml of a saturated E. coli LB culture, pellet cells in a standard bench top micro centrifuge for 30 sec at 11,000 x g.
- discard the supernatant
- for cell lysis add 250 µl Buffer A1. Re-suspend the cell pellet completely by pipetting up and down
- add 250 µl Buffer A2
- mix gently by inverting the tube 10 times and Incubate at room temperature for up to 5 min
- 55 - add 300 µl Buffer A3. Mix thoroughly by inverting the tube 10 times
- centrifuge for 5 min at 11,000 x g at room temperature
- place a NucleoSpin® Plasmid Column in a collection tube (2 ml) and load a 750 µl of the supernatant onto the column.
- centrifuge for 1 min at 11,000 x g.

EP 2 881 461 A1

- discard flow-through and place the NucleoSpin® Plasmid Column back into the collection tube (2 ml)
- for wash the membrane with DNA: Add 600 µl Buffer A4 (supplemented with ethanol).
- centrifuge for 1 min at 11,000 x g.
- discard flow-through and place the NucleoSpin® Plasmid Column back into the collection tube (2 ml)
- 5 - dry silica membrane: centrifuge for 2 min at 1 1,000 x g and discard the collection tube (2 ml)
- elute DNA: place the NucleoSpin® Plasmid Column in a 1.5 ml micro centrifuge tube and add 50 µl H₂O and incubate for 1 min at room temperature.
- centrifuge for 1 min at 11,000 x g
- measure the DNA-concentration with the nanodrop
- 10 - DNA store at -20°C

1. D) Linearisation of the pCRII-hoct4, pCRII-hSox2, pCRII-hKlf4 plasmids for the in vitro transcription

[0101]

- 15 - pCRII-hoct4 digest with BamHI
- pCRII-hSox2 digest with HindIII
- pCRII-hKlf4 digest with HindIII

20 Preparation of digest on ice:

[0102]

- 25 - 5 µl 10x Buffer
- 2 µg Plasmid
- 2 µl Restriction-Enzyme
- to 50 µl DEPC-H₂O
- incubation for 1 h at 37°C (thermo block; Eppendorf)
- 30 - heat inactivation for 20 min by the specific temperature of the enzyme
- heat inactivate both enzyme for 20 min at 80°C

1. E) Purification of the linearized pCRII-hoct4, pCRII-hSox2, pCRII-hKlf4 plasmids with QIAquick PCR Purification Kit (from Qiagen)

[0103]

- add 5 volumes of Buffer PB to 1 volume of the digest sample and mix
- place a QIAquick spin column in a provided 2 ml collection tube
- 40 - to bind DNA, apply the sample to the QIAquick column and centrifuge for 60 s
- discard flow-through
- place the QIAquick column back into the same tube
- to wash, add 0.75 ml Buffer PE to the QIAquick column and centrifuge for 60 s
- discard flow-through and place the QIAquick column back in the same tube
- 45 - to dry the membrane, centrifuge the column for an additional 1 min
- place QIAquick column in a 1.5 ml micro centrifuge tube
- to elute DNA, add 10 µl H₂O to the centre of the QIAquick membrane, let the column stand for 1 min, and centrifuge the column for 1 min
- measure the DNA-concentration with the nanodrop
- 50 - store DNA at -20°C

1. F) in vitro transcription of the linearized pCRII-hoct4, pCRII-hSox2, pCRII-hKlf4 plasmids with mMessage mMachine high yield capped RNA Transcription Kit (from Ambion) and add a poly(A) tail to RNA transcripts (Poly(A)-Tailing Kit from Ambion)

[0104]

Preparation of the in vitro transcription (mMESSAGE mMACHINE reaction):

[0104]

EP 2 881 461 A1

- to 20 μ l nuclease-free water
- 10 μ l 2x NTP/CAP
- 2 μ l 10x reaction buffer
- 1 μ g linear template plasmid
- 5 - 2 μ l enzyme mix

- pipette the mixture up and down gently
- short centrifugation to collect the reaction mixture at the bottom of the tube
- incubation for 2 h at 37°C
- 10 - add 1 μ l TURBO DNase to the mRNA and mix well
- incubate at 37°C for 15 min
- direct after the DNase-treated reaction add the poly(A)-tail to the mRNA

Preparation for poly(A)-tail reaction:

15

[0105]

- 20 μ l mMESSAGE mMACHINE reaction
- 36 μ l nuclease-free water
- 20 - 20 μ l 5x E-PAP Buffer
- 10 μ l 25 mM MnCl₂
- 10 μ l mM ATP
- 4 μ l E-PAP

- 25 - mix gently
- incubate at 37°C for 1 h
- place reaction on ice
- lithium chloride precipitation of the mRNA with poly(A)-tail:
- add 30 μ l LiCl Precipitation Solution
- 30 - mix thoroughly
- chill for 30 min at -20°C
- centrifuge at 4°C for 15 min at maximum speed to pellet the RNA
- remove the supernatant
- wash the pellet once with 1 ml 70% ethanol
- 35 - centrifuge at 4°C for 15 min at maximum speed to pellet the RNA
- remove the 70% ethanol
- air-dry the pellet
- solve the RNA-Pellet with 30-50 ml nuclease-free-water
- the concentration of the RNA is measured with the nanodrop
- 40 - the quality of the RNA is measured with the Agilent nano-chip

2. Preparation of target cells

2. A) Preparation of mouse and rat MSCs

45

[0106]

- kill the rat or mouse with CO₂-gassing
- spray the rats and mice with 70% Ethanol to kill of bacteria and fungal spores
- 50 - remove the coat from the skin
- remove the back legs cleanly at the hip joint
- under sterile conditions, remove all soft tissue and separate the bones
- remove the growth plates both femur and tibia
- insert holes with a needle into the bones on both ends
- 55 - place the bones in eppendorf tubes (for mice) or in falkon tubes (for rats) and spin at 2000 rpm for 1 min (all of the bone marrow will be deposited in the bottom of the tube sitting in spacers); remove the bones and spacer
- re-suspend the marrow in 0,5 ml medium (DMEM low glucose; 10 % FCS; 1 % Pen/Strep)
- disseminate the marrow of one leg from a rat in 1 T-75 flask with 12 ml medium

EP 2 881 461 A1

- disseminate the marrow of two legs from a mouse in 1 10 cm petri-dish with 12 ml medium

2. B) Preparation of human MSC

5 **[0107]**

- get a bone marrow aspirate
- re-suspend in DMEM (low glucose, 10%FCS)
- plate out in a tissue culture flask
- 10 - growth for 5 days and then change media
- thereafter change the medium twice weekly
- culture in tissue culture flask until 80% confluency and subculture until needed

2. C) Preparation of mouse and rat fibroblasts

15

[0108]

- cut of the tail
- shave the tail with a scalpel
- 20 - spray the tail with 70% ethanol to kill of bacteria and fungal spores
- remove the skin from the tail
- place the skin in a 10 cm petri dish
- under sterile conditions, cut the skin in small pieces (5 x 5 mm)
- digest the skin-pieces with 0,05 % Trypsin EDTA for 20 min in 37°C CO2-Incubator
- 25 - wash the trypsin from the skin-dishes with medium (DMEM high glucose, 10 % FCS, 1 % Pen/Strep), remove the medium and wash again for 3-4 times
- then incubate the skin pieces in 37°C CO2-Incubator and change the medium every day, after 1 week the fibroblasts growth out

30 2. D) Preparation of human fibroblasts

[0109]

- place prepuce in petri dish
- 35 - wash two times with PBS
- remove fat
- wash with PBS one time
- cut the skin in small pieces (2 mm)
- add 10ml dispase (2 U/ml)
- 40 - incubate at 4°C for 16-18 h
- discard dispase solution
- add 5 ml PBS
- separate dermis and epidermis
- transfer dermis to new dish and add 10ml collagenase (500 U/ml)
- 45 - make very small pieces
- transfer pieces into a 50 ml falcon tube with solution and incubate for 45 min (37°C; 5% CO2)
- centrifuge at 1000rpm for 5 min
- discard supernatant and resuspend pellet in DMEM (10% FCS)
- centrifuge again
- 50 - resuspend pellet in 2 ml DMEM (10% FCS) and transfer into a T75 cell culture flacon
- expanded cells until use

55

3. mRNA Transfection

3. A) mRNA-transfection of human fibroblasts, human MSC, rat fibroblasts, rat MSC, mouse fibroblasts and mouse MSC with AMAXA, EugeneHD, Lipofectamine™ LTX Reagent and PLUS™ Reagent

1) AMAXA-Transfection with the Human Dermal Fibroblast Nucleofector® Kit (6 well-plate):

Preparation for one electroporation in certified Amaxa cuvette:

[0110]

- mRNA of oct4, sox2 and klf4 in sum of 2 µg
- 4x10⁵ cells
- 100 µl Nucleofector® Solution
- choose the program U-023 by the Amaxa-electroporation-machine
- re-suspend the cells in the cuvette with 500 µl fibroblast or MSC-Medium
- provide 5 ml fibroblast or MSC-Medium with or without Cocktail in every well of a 6 well-plate
- plate out 100.000 cells in each well of a 6 well-plate

Cocktail composition:

[0111]

- Resveratrol 0,05 mM
- Selenium 0,1 µM
- EGCG ((-)-Epigallocatechin gallate) 0,01 µM
- TSA (Trichostatin A) 0,015 µM
- Reversin 1 µM
- VPA (2-Propylpentanoic acid free acid) 6 µM
- 5'Aza (5-Aza-2'-deoxycytidine) 1 µM
- at day 1: the cocktail is with 5'Aza and without TSA; after 48 hours 5'Aza replaced by TSA
- every 72 hours new transfection with FuGENE® HD Transfection Reagent (Roche)

2) Transfection FuGENE® HD Transfection Reagent (Roche)

[0112] >

- before transfection: change to antibiotic free medium

Transfection procedure

[0113]

- Dilute mRNA with serum-free and antibiotic-free medium to a concentration of 2 µg mRNA at a volume of 100 µl for each well (6well-plate)
- Pipet the 8 µl FuGENE® HD Transfection Reagent (Ratio: 8:2 Transfection reagent to mRNA) directly into the medium pipette up and down
- Incubate the transfection reagent: mRNA complex for 15 minutes at room temperature
- Add the transfection complex to the cells in a drop-wise manner
- Swirl the wells to ensure distribution over the entire plate surface
- after 4-6 hours change to medium (contains 10 % FCS, 1 % Pen/Strep) with or without cocktail
- one transfected 6 well plate incubate at 21 % O₂-condition (normoxy) and a second plate incubate at 1 % O₂-condition (hypoxia) at 37°C incubator

EP 2 881 461 A1

3) Alternative transfection with Lipofectamine™ LTX Reagent or PLUS™ Reagent (Invitrogen)

a) Transfection FuGENE® HD Transfection Reagent (Roche)

[0114]

- plate out 7000 cells in 500 µl medium per well of a 24 well-plate
- incubate over night
- for transfection: change to antibiotic free medium
- lute 0,5 µg mRNA in 25 µl serum-free and antibiotic-free medium for each well (24well-plate)
- pipette the FuGENE® HD Transfection Reagent 2 µl (Ratio: 8:2 Transfection reagent to mRNA) directly into the medium
- pipette up and down
- incubate the transfection reagent: mRNA complex for 15 minutes at room temperature
- add the transfection complex to the cells in a drop-wise manner
- swirl the wells to ensure distribution over the entire plate surface
- after 4-6 hours change to medium (contains 10 % FCS, 1 % Pen/Strep) with or without cocktail

b) Lipofectamine™ LTX Reagent and PLUS™ Reagent (Invitrogen)

[0115]

- plate out 7000 cells in 500 µl Medium per well of a 24 well-plate
- incubation over night
- before transfection: change to antibiotic free medium
- dilute 0,5 µg mRNA in 100 µl serum-free and antibiotic-free medium for each well (24well-plate)
- mix gently
- mix PLUS Reagent gently before use
- add 0,5 µl PLUS™ Reagent in the mRNA-Medium mix, mix gently and incubate 5 min at room temperature mix
- Lipofectamine™ LTX Reagent gently before use
- add 1,25 µl directly to the diluted mRNA); mix gently
- incubate for 30 min at room temperature
- add the 100 µl mRNA- Lipofectamine™ LTX Reagent complex
- to the well
- mix gently by rocking the plate back and forth
- incubate the cells at 37°C in the CO2 incubator for 4-6 hours
- change to medium with or without cocktail
- during the optimization of the transfection efficiency → increase of the amount of mRNA concentration at 1 µg per well (24 well plate)
- every 72 h repeat the transfection with FuGENE® HD or Lipofectamine™ LTX Reagent and PLUS™ Reagent

4. Protease inhibitor treatment (MG132) to increase the half-life of the proteins produced by the transfected mRNA:

[0116]

- 48h after transfection: treatment of two wells in every plate with MG-132 (10 µM/well) with and without cocktail for 6 h, then change medium

5. Results

[0117] Analysis of mRNA amount (per PCR) of the transfected or internal genes (oct4, nanog, hTERT, sox2, klf4) and promoter analysis (of nanog, sox, oct4)

[0118] The reprogramming results are set forth in figures 1 to 8

6. Tools and Methods

6.1 RNA-Isolation with TriFaSt™ (Peglab)

[0119]

- 1 ml Trifast per 10 cm² of the culture dish area
- samples can be stored for a long time at -80°C or be directly used
- samples should be kept for 5 minutes at room temperature
- addition of 0.2 ml of chloroform
- shake samples by hand vigorously for 15 seconds
- incubation for 3 minutes at room temperature
- centrifugation at 12.000 x g
- transfer the aqueous phase with RNA to new tube (save the interphase and organic phase at 4°C for the isolation of DNA and proteins).
- precipitation of the RNA with 0.5 ml of Isopropanol per 1 ml of Tri-Fast™ used for the initial homogenization.
- incubation on ice for 15 min
- centrifuge for 10 minutes at 4°C at 12.000 g
- remove the supernatant
- wash the RNA pellet twice with 75% ethanol by vortexing
- subsequent centrifugation for 8 minutes at 7,500 x g (4°C)
- remove the excess isopropanol from the RNA pellet by airdrying
- re-suspend the RNA pellet in Rnase-free water (DEPC-H₂O) → 30 µl - 50 µl
- dissolve the RNA pellet by passing the solution through a pipette tip several times
- incubating the solution for 10 min at 55°C
- pipetting it up and down.
- Heating the sample at 55-60°C might help to dissolve the pellet
- measure the RNA-Concentration → NanoDrop
- samples store at -80°C for 2-3 months

6.2 DNA-Isolation:

[0120]

- Remove any left aqueous phase after RNA removal
- precipitate the DNA with 0.3 ml of 100% ethanol per ml Tri-Fast™
- mix well by inversion
- store the samples at room temperature for 2-3- minutes
- centrifugation at 2,000 x g at 4°C for 5 minutes
- move the DNA supernatant (store it at 4°C for the protein isolation)
- DNA pellet washed twice with 1 ml 0.1 M sodium citrate in 10% ethanol
- At each wash step keep the DNA in 0.1 M sodium citrate /10% ethanol for 30 minutes at room temperature (with periodic mixing)
- centrifuge at 4°C for 5 minutes at 2,000 x g
- after these two washes suspend the DNA pellet in 2 ml of 75% ethanol
- keep it at room temperature with periodic mixing for 15 minutes
- centrifuge at 2,000 x g for 5 minutes at 4°C
- dry the DNA pellet briefly for 5-10 minutes under vacuum and
- dissolve it in 8 mM NaOH by slowly passing the pellet through a wide bore pipet.
- Try to adjust the final concentration of DNA to 0.2-0.3 µg/µl with 8 mM NaOH

6.3 RNA treatment with DNase I (Fermentas):

[0121]

- 1 µg RNA
- 1 µl 10X reaction buffer with MgCl₂
- 1 µl (1 u) DNase

- to 9 µl DEPC-H₂O
- incubate at 37°C for 30 minutes
- inactivation of DNase I: Add 1 µl 25mM EDTA and incubate at 65°C for 10 min

6.4 RT-PCR with SuperScript™ III Reverse Transcriptase (Invitrogen)

Reaction condition:

[0122]

- 1 µl oligo(dT)₂₀ Primer
- 1 µg RNA
- 1 µl 10 mM dNTP Mix (10 mM each dATP, dGTP, dCTP and dTTP)
- to 13 µl DEPC-H₂O
- heat mixture to 65°C for 5 minutes
- incubate on ice for 1 min

Add:

[0123]

- 4 µl 5X First-Strand Buffer
- 1 µl 0.1M DTT
- 1 µl SuperScript™ III RT (200 units/µl)
- mix by pipetting gently up and down
- incubate at 50°C for 60 min
- inactivate the reaction by heating at 70°C for 15 minutes
- store the cDNA at -20°C

6.5 PCR of human oct4 (control the human fibroblasts):

[0124] Primersequence: hoct4_S: gaggatcaccctgggatatacahoct4_as: agatggtcgtttggctgaatac
[0125] Product size: 100 bp

6.6 PCR with Patinum Taq-Poymerase (Invitrogen)

Preparation of PCR-reaction on ice:

[0126]

- 5 µl 10X PCR Buffer
- 1 µl 10 mM dNTP mixture 0.2 mM each
- 1.5 µl 50 mM MgCl₂
- 1 µl Primer mix (10 µM each) 0.2 µM each
- 1 µl Template DNA
- 0,2 µl Platinum® Taq DNA Polymerase 1.0 unit
- to 50 µl DEPC-H₂O

PCR-Program (Biometra Tprofessional):

[0127]

EP 2 881 461 A1

	95°C	2 min	
	95°C	30 sec	
5	60°C	30 sec	← 35 x
	70°C	30 sec	
	70°C	10 min	
10	4°C	for storage	

PCR-control with 3% TAE-agarose-gel for electrophoresis

15 6.7 Protocol to produce iPS cells

6.7.1 BD Matrigel™ hESC-qualified Matrix

20 [0128]

- put the sterilized tip box and eppendorf tubes over night in - 20°C freezer
- thaw the Matrigel bottle on ice in the 4°C fridge overnight
- aliquot Matrigel for hESC upon arrival, store at -80°C, only thaw once and do not re-freeze to avoid breakdown of growth factors
- 25 - for coating purposes, dilute Matrigel appropriately by using serum-free medium (0.3 µg/µl for iPS, 1 µg/µl for hESC)
- add 50 µl Matrigel-dilution per cm² growth surface
- incubate 60 min at RT under sterile conditions or overnight at 4°C
- soak off remaining Matrigel/medium
- Medium: mTeSR1 (Stem Cell Technology)

30 [0129] Notes: Coating recommendations (0.3 µg/µl) is of course dependant on the cell type that you are using to generate iPS. It is recommended to coat (not gel!) plastics for hESC culture using 1 µg Matrigel/µl. Use plates immediately or store for max 7 days at 4°C covered with serum-free medium under aseptical conditions (sealed).

35 [0130] Please note that you always should process, store and use your coated Matrigel plates exactly the same way to avoid variabilities (mainly through breakdown of growth factors). In the beginning or for establishment it necessary to titrate a coating volume and - concentration (maybe 3 dilutions 0.3, 0.6, 1 µg/ul) that suit your specific type of cells best.

6.7.2 BD Matrigel™ Basement Membrane Matrix, Growth Factor Reduced (GFR)

40 [0131]

- aliquot the matrigel such as hESC-qualified Matrigel
- thaw tube overnight on ice at 4°C
- dilute with 6 ml cold basal media and mix well
- 45 - add 1 ml per well of 6 well plate
- incubate the plate at room temperature for one hour or overnight at 4°C
- plate may either be used immediately or stored at 4°C (plate are be good for least one week)
- remove the excess liquid and wash once with basal medium
- basal medium component: D-MEM/F-12; 20% KO Serum Replacer; 1% Non-essential Amino Acids; 1mM L-Glutamine, 0.1 mM 2-Mercaptoethanol; 100 ng/ml bFGF
- 50 - use mouse cells then add LIF-supernatant to the basal medium

6.7.3 Production of LIF-supernatant

55 [0132]

- coat petri dish (145 mm) with 0,1 % gelatine (Bovine Type x?, Sigma)
- plate 3x10⁶ LIF producing feeder cells SNL in every dish

EP 2 881 461 A1

- Medium component: D-MEM high glucose, 10% FCS, 1 % Pen/Strep; 1 % L-Glutamine
- after 24 hours collect the medium from the dish and filter through a 0,22 μm filter
- aliquote the medium containing LIF in 500 μl aliquots and store at -20°C
- change media after 24 hours or 48 hours

5

10

15

20

25

30

35

40

45

50

55

SEQUENCE LISTING

<110> Fraunhofer-Gesellschaft zur Förderung der angewandten
Forschung e. V.

<120> Reprogramming cells toward a pluripotent state

<130> FBP25769-A

<160> 28

<170> PatentIn version 3.5

<210> 1

<211> 2098

<212> DNA

<213> Homo sapiens

<400> 1

```

attataaatc tagagactcc aggatttttaa cgttctgctg gactgagctg gttgcctcat 60
gttattatgc aggcaactca ctttatccca atttcttgat acttttcctt ctggagggtcc 120
tattttctcta acatcttcca gaaaagtctt aaagctgcct taaccttttt tccagtgccac 180
ctcttaaatt ttttctcctt cttcctctat actaacatga gtgtggatcc agcttgccc 240
caaagcttgc cttgctttga agcatccgac tgtaaagaat cttcacctat gcctgtgatt 300
tgtgggcctg aagaaaacta tccatccttg caaatgtctt ctgctgagat gcctcacacg 360
gagactgtct ctctcttcc ttcctccatg gatctgctta ttcaggacag ccctgattct 420
tccaccagtc ccaaaggcaa acaaccctt tctgcagaga agagtgtcgc aaaaaaggaa 480
gacaagggtcc cggtaagaa acagaagacc agaactgtgt tctcttccac ccagctgtgt 540
gtactcaatg atagatttca gagacagaaa tacctcagcc tccagcagat gcaagaactc 600
tccaacatcc tgaacctcag ctacaaacag gtgaagacct gggtccagaa ccagagaatg 660
aaatctaaga ggtggcagaa aaacaactgg ccgaagaata gcaatgggtg gacgcagaag 720
gcctcagcac ctacctacc cagcctttac tcttctacc accagggatg cctgggtgaac 780
ccgactggga accttccaat gtggagcaac cagacctgga acaattcaac ctggagcaac 840
cagaccaga acatccagtc ctggagcaac cactcctgga aactcagac ctggtgcacc 900
caatcctgga acaatcaggc ctggaacagt cctctctata actgtggaga ggaatctctg 960
cagtccgtgca tgcagttcca gccaaattct cctgccagtg acttgaggc tgccttgaa 1020
gctgctgggg aaggccttaa tgtaatacag cagaccacta ggtattttag tactccacaa 1080
accatggatt tattcctaaa ctactccatg aacatgcaac ctgaagacgt gtgaagatga 1140
gtgaaactga tattactcaa ttccagtctg gacactggct gaatccttc tctccctcc 1200
tcccatccct cataggattt ttctgtttg gaaaccacgt gttctggtt ccatgatgcc 1260
catccagtca atctcatgga ggttgagta tgggtggagc ctaatcagcg aggtttcttt 1320
tttttttttt ttctattgg atcttcttg agaaaatact tttttttttt ttttttttga 1380
aacggagtct tgcctgtcg cccaggctgg agtgagctgg agcggcttg gctcactgca 1440
agctccgtct cccgggttca cgccattctc ctgccctcagc ctcccagca gctgggacta 1500
caggcgcccg ccacctcgcc cggctaatat tttgtatttt tagtagagac ggggtttcac 1560
tgtgttagcc aggatggtct cgatctcctg acctgtgat ccaccgcct cggcctccct 1620
aacagctggg atttacaggc gtgagccacc gcgccctgcc tagaaaagac attttaataa 1680
ccttggtctg cgtctctggc tatagataag tagatctaact actagtttg atattcttag 1740
ggtttagaat ctaacctcaa gaataagaaa tacaagtaca aattggtgat gaagatgtat 1800
tcgtattgtt tgggattggg aggcttttgat tattttttta aaactattga ggtaaagggt 1860
taagctgtta catacttaat tgatttctta ccgttttttg ctctgttttg ctatctccc 1920
taattgtttg gttgtgctaa tctttgtaga aagaggtctc gtatttgctg catcgtaatg 1980
acatgagtac tgctttagtt ggtttaagtt caaatgaatg aaacaactat ttttcttta 2040
gttgatttta ccctgatttc accgagtgtt tcaatgagta aatatacagc ttaaacad 2098

```

<210> 2

<211> 1356

<212> DNA

<213> Mus musculus

<400> 2

```

tctatcgctt tgagccgttg gccttcagat aggttgattt gggttggtgtc ttgtcttttc 60
tgtgggaagg ctgaggctca cttccttctg acttcttgat aattttgcat tagacattta 120
actcttcttt ctatgatctt tccttctaga cactgagttt tttggttgtt gcctaaaacc 180
ttttcagaaa tcccttccct cgccatcaca ctgacatgag tgtgggtctt cctgggtccc 240
acagtttgcc tagttctgag gaagcatcga attctgggaa cgcctcatca atgcctgcag 300
tttttcatcc cgagaactat tcttgcttac aagggtctgc tactgagatg ctctgcacag 360
aggctgcttc tccctgcctt tcctctgaag acctgcctct tcaaggcagc cctgattctt 420
ctaccagtc caaacaaaag ctctcaagtc ctgaggctga caaggccct gaggaggagg 480
agaacaaggc ccttgccagg aagcagaaga tggggactgt gttctctcag gccagctgt 540
gtgcactcaa ggacagggtt cagaagcaga agtacctcag cctccagcag atgcaagaac 600

```

EP 2 881 461 A1

	tctcctccat	tctgaacctg	agctataagc	aggttaagac	ctggtttcaa	aaccaaagga	660
	tgaagtgcaa	gcggtggcag	aaaaaccagt	ggttgaagac	tagcaatggt	ctgattcaga	720
	agggtcagc	accagtggag	tatcccagca	tccattgcag	ctatcccag	ggctatctgg	780
	tgaacgcac	tggaaacctt	tccatgtggg	gcagccagac	ttggaccaac	ccaacttggg	840
5	gcagccagac	ctggaccaac	ccaacttggg	acaaccagac	ctggaccaac	ccaacttggg	900
	gcagccaggg	ctggaccgct	cagtccctgga	acggccagcc	ttggaatgct	gctccgctcc	960
	ataacttcgg	ggaggacttt	ctgcagcctt	acgtacagtt	gcagcaaac	ttctctgcca	1020
	gtgatttggg	ggtgaatttg	gaagccacta	gggaaagcca	tgcgcatttt	agcaccac	1080
	aagccttggg	attattcctg	aactactctg	tgactccacc	agggtgaaata	tgagacttac	1140
10	gcaacatctg	ggcttaaagt	cagggcaaaag	ccagggttcct	tccttcttcc	aaatatatttc	1200
	atattttttt	taaagattta	tttattcatt	atatgtaagt	acactgtagc	tgtcttcaga	1260
	cactccagaa	gagggcgctc	gatcttggtt	cgtatggttg	tgagccacca	tgtggttgct	1320
	gggatttgaa	ctcctgacct	tcggaagagc	agtcgg			1356
	<210>	3					
15	<211>	2358					
	<212>	DNA					
	<213>	Rattus norvegicus					
	<400>	3					
	tcagataggc	tgatttcgag	tctttctctt	ttgtgggaag	accgaggctc	gcttcttttt	60
20	ggcttgttga	ctctttttaca	tctggacatt	taactcttac	ttttaagatc	tttccctcta	120
	gacactgagt	tttaaagtct	taactttttg	gttggttaaaa	actttttttt	ttttaaagtc	180
	ccttcccttg	ccgttgggct	gacatgagcg	tggtatctttc	tggtccccac	agtctgccta	240
	gttgtgagga	agcatcgaac	tctggggatt	cctcgccgat	gcctgccgtt	catcttctctg	300
	aggaaaatta	ttcttgctta	caagtgtctg	ctactgagat	gctctgcaca	gagactgcct	360
	ctcctccgcc	ttcctctggg	gacctacctc	ttcaagatag	ccctgattct	tctagcaatc	420
25	ccaagctaaa	gctgtctggg	cccagggctg	acgagggccc	tgagaagaaa	gaagagaaca	480
	aggctcctcac	caagaagcag	aagatgcgga	ctgtgttctc	tcaggcccag	ttgtgtgcac	540
	tcaaggatag	gtttcagagg	caaaggtacc	tcagcctcca	gcagatgcaa	gatctctcta	600
	ccattctgaa	ctcagactat	aagcaggtga	agacctgggt	ccaaaaccac	agaatgaagt	660
	gcaagaggtg	gcagaaaaac	caatggttga	agactagcaa	cggcctgact	cagaagggct	720
30	cagcgccggg	ggagtatccc	agcatccatt	gcagctattc	tcagggtctat	ctgatgaacg	780
	cgtctggaaa	ccttccagta	tggggcagtc	agacctggac	caaccacaact	tggacaacac	840
	agacctggac	caaccacaacc	tggagcaaac	agacctggac	caaccacaact	tggagcaaac	900
	aggcctggag	cactcagtc	tggtgtactc	aggcctggaa	cagccagact	tggaacgctg	960
	ctccgctcca	taacttcggg	gaggactccc	tgagcctta	tgtgccgttg	cagcaaaaact	1020
	tctcccgag	tgatttggag	gcgaatttgg	aagccactag	ggaaagccag	gcccatttta	1080
35	gtaccccgca	agccttggaa	ttgttctgta	actactccgt	gaattctcca	gacgaaatat	1140
	gaggtttaca	caacaactgg	gcttaaagtc	agggcagggc	cagggctcagc	tttcttctct	1200
	cttccaaaga	gttttatatt	gttcttattt	tttttttaaat	tattattttg	tttttgtttt	1260
	ttgtttatca	aggtaggggt	tctctgtgtg	gttctggctg	tcctggaatt	cactctgtag	1320
	accaggctgg	cctcgtactc	agagatctgc	ctacttttgc	ctcctgaagg	ctagggctaa	1380
	agattttcta	aagattttca	tagtttttat	ttttttaatt	attatctgtt	ttcatgtttg	1440
40	tgtttttttg	ttttgttttt	gtttttgttt	ttgtttatca	agatagggtt	tctctgtgtg	1500
	gctctagtag	tcccggaaac	tggctctgta	gaccaggctg	tccttgaaact	cagaaatctg	1560
	cctttgcctc	cggactgcgg	ggactaaagg	cagtatataa	ccacctggca	cattgttttt	1620
	atttttattc	ttttggtgcc	agaaagcaaa	cctaggactt	tgagctgggc	acccactcaa	1680
	ccactgagct	ctgtttgcga	cccccggtt	ggctgcattt	gtctgagctg	ggtaacttgt	1740
45	ctttttttcc	gtgttaacga	tgggcttcgg	agacagtga	ctatacactc	tatcctcccc	1800
	cagggtctcac	acaccacccc	tactccatac	caaccagggc	ttgtctgtct	tttttttttt	1860
	tggagctgag	gactgaaccc	agggccttgc	gctttctagg	caagcgctct	acctctgagc	1920
	taaatacccca	acccttgtct	gtctttttg	aagcttgggt	cttgggtgtg	actgtgtatc	1980
	gttttgaggg	gtgaggttta	aaagtataca	aattataaag	attcatgcag	atatgggtggc	2040
	tcctctcaag	gacgagacag	aaggatcacc	agtttgaggc	tatctcagat	ataaaataag	2100
50	ttcaagacca	gcctgtacta	tgtctaaata	gtaagacagc	atctcaacaa	aataataaaa	2160
	ctaaggtaag	gagataaaaag	taaagtctca	acaaaataca	agatctcgcc	tgttacagtt	2220
	ctttgatttc	ctccgtgtct	ttgcagttcc	gccaaagaggc	ttctatgtta	atatctgtag	2280
	aaagatgttt	atatttgact	gtaccatgat	aaaccagtgc	cagctggact	agtttaataa	2340
	aaacactaat	tttaccaca					2358
55	<210>	4					
	<211>	2518					
	<212>	DNA					

<213> Homo sapiens

<400> 4

5 ctattaactt gttcaaaaaa gtatcaggag ttgtcaaggc agagaagaga gtgttttcaa 60
 aagggggaaa gtagttttgct gcctctttta gactaggact gagagaaaga agaggagaga 120
 gaaagaaagg gagagaagtt tgagccccag gcttaagcct ttccaaaaaa taataataac 180
 aatcatcggc ggcggcagga tcggccagag gaggaggaa gcgctttttt tgatcctgat 240
 tccagtttgc ctctctcttt ttttcccca aattattctt cgcctgattt tcctcgcgga 300
 gccctgogct cccgacaccc ccgcccgcct cccctcctcc tctccccccg ccgcgaggcc 360
 ccccaaagtc ccggccgggc cgagggtcgg cggccgcccg cgggcccggc ccgcgcacag 420
 cgcccgcgatg tacaacatga tggagacgga gctgaagccg ccgggcccgc agcaaaacttc 480
 10 gggggggcggc ggcggaact ccaccgcggc ggcgccggc ggcaaccaga aaaacagccc 540
 ggaccgcgctc aagcgggcca tgaatgcctt catggtgtgg tcccgcgggc agcggcgcaa 600
 gatggcccag gagaacccca agatgcacaa ctcgagatc agcaagcgc tgggcgccga 660
 gtggaaactt ttgtcggaga cggagaagcg gccgttcac gacgaggcta agcggtctgcg 720
 agcgtgcac atgaaggagc acccgatta taaataccgg ccccgcgga aaaccaagac 780
 15 gctcatgaag aaggataagt acacgtgcc cggcggtctg ctggcccccg gcggcaatag 840
 catggcgagc ggggtcgggg tgggcgcccg cctgggcgcg ggcgtgaacc agcgcattga 900
 cagttacgag cacatgaacg gctggagcaa cggcagctac agcatgatgc aggaccagct 960
 gggctacccg cagcaccgga gcctcaatgc gcacggcgca gcgcagatgc agcccatgca 1020
 ccgctacgac gtgagcgccc tgcagtaca ctccatgacc agctcgaga cctacatgaa 1080
 cggctcggcc acctacagca tgtcctactc gcagcaggc acccctggca tggctcttgg 1140
 20 ctccatgggt tcggtggtca agtccgagggc cagctccagc cccctgtggg ttacctcttc 1200
 ctcccactcc agggcgccct gccaggccgg ggacctccgg gacatgatca gcatgtatct 1260
 ccccggcgccc gaggtgccgg aaccgcccgc cccagcaga cttcacatgt cccagcacta 1320
 ccagagcggc ccggtgcccg gcacggccat taacggcaca ctgcccctct cacacatgtg 1380
 agggccggac agcgaactgg aggggggaga aattttcaaa gaaaaacgag ggaaatggga 1440
 25 ggggtgcaaa agaggagagt aagaaacagc atggagaaaa cccggtacgc tcaaaaagaa 1500
 aaaggaaaaa aaaaaatccc atcacccaca gcaaatgaca gctgcaaaag agaacaccaa 1560
 tcccatccac actcacgcaa aaaccgcat gccgacaaga aaacttttat gagagagatc 1620
 ctggacttct ttttggggga ctatttttgt acagagaaaa cctggggagg gtggggaggg 1680
 cgggggaatg gaccttgtat agatctggag gaaagaaagc tacgaaaaac tttttaaaag 1740
 ttctagtggg acggtaggag ctttgaggga agtttgcaaa agtctttacc aataatattt 1800
 30 agagctagtc tccaagcgac gaaaaaaatg ttttaatat ttgcaagcaac ttttgtacag 1860
 tatttatcga gataaacatg gcaatcaaaa tgtccattgt ttataagctg agaatttgcc 1920
 aatatttttc aaggagaggc ttcttgctga attttgattc tgcagctgaa atttaggaca 1980
 gttgcaaacg tgaaaagaag aaaattattc aaatttggac attttaattg ttttaaaatt 2040
 gtacaaaagg aaaaaattag aataagtact ggcgaaacat ctctgtggtc ttgtttaaaa 2100
 agggcaaaaag ttttagactg tactaaattt tataaactac tgttaaaagc aaaaatggcc 2160
 35 atgcaggttg acaccgttgg taatttataa tagcttttgt tcgatcccaa ctttccattt 2220
 tgttcagata aaaaaaacca tgaaattact gtgtttgaaa tattttctta tgggttgtaa 2280
 tatttctgta aatttattgt gatattttta gggtttcccc cctttatttt ccgtagttgt 2340
 attttaaaag attcggctct gtattatttg aatcagctct ccgagaatcc atgtatatat 2400
 ttgaactaat atcatcctta taacaggtac attttcaact taagttttta ctccattatg 2460
 40 cacagtttga gataaataaa tttttgaaat atggacactg aaaaaaaaaa aaaaaaaa 2518

<210> 5

<211> 2457

<212> DNA

<213> Mus musculus

<400> 5

45 ctattaactt gttcaaaaaa gtatcaggag ttgtcaaggc agagaagaga gtgttttcaa 60
 aaagggaaaa gtactttgct gcctctttta gactagggct gggagaaaga agaggagaga 120
 gaaagaaagg agagaagttt ggagcccag gcttaagcct ttccaaaaac taatcacaaac 180
 aatcgcgggc gcccgaggag gagagcgctt gttttttcat cccaattgca cttcgcccg 240
 50 ctogagctcc gtttcccccc aactattctc cgcagatct ccgcgcagg ccgtgcacgc 300
 cgaggccccc gcccgcgccc cctgcacccc ggcccccgag cgcggccccc acagtcccgc 360
 ccgggcccag ggttgccggc cgccggcggg ccgcgcccgc ccagcggccc catgtataac 420
 atgatggaga cggagctgaa gccgccgggc ccgcagcaag cttcgggggg cgcgccgga 480
 ggaggcaacg ccacggcggc ggcgaccggc ggcaaccaga agaacagccc ggaccgcgc 540
 aagagcccca tgaacgcctt catggtatgg tcccgggggc agcggcgtaa gatggcccag 600
 55 gagaacccca agatgcacaa ctcgagatc agcaagcgc tgggcgcgga gtggaaactt 660
 ttgtccgaga ccgagaagcg gccgttcac gacgaggcca agcggtctgc cgtctgcac 720
 atgaaggagc acccgatta taaataccgg ccgcggcgga aaaccaagac gctcatgaag 780

EP 2 881 461 A1

	aaggataagt	acacgcttcc	cggaggcttg	ctggcccccg	gcggaacag	catggcgagc	840
	ggggttgggg	tgggcgcggg	cctgggtgcg	ggcgtgaacc	agcgcatgga	cagctacgcg	900
	cacatgaacg	gctggagcaa	cggcagctac	agcatgatgc	aggagcagct	gggctacccg	960
	cagcaccggc	gcctcaacgc	tcacggcgcg	gcacagatgc	aaccgatgca	ccgctacgac	1020
5	gtcagcgccc	tgcatgacaa	ctccatgacc	agctcgcaga	cctacatgaa	cggctcggcc	1080
	acctacagca	tgtcctactc	gcagcagggc	accccggta	tggcgctggg	ctccatgggc	1140
	tctgtggtca	agtccgaggc	cagctccagc	cccccggtg	ttacctcttc	ctccactcc	1200
	agggcgccct	gccaggccgg	ggacctccgg	gacatgatca	gcatgtacct	ccccggcgcc	1260
	gaggtgccc	agcccgtgc	gcccagtaga	ctgcacatgg	cccagcacta	ccagagcggc	1320
10	ccggtgccc	gcacggccat	taacggcaca	ctgcccctgt	cgcacatgtg	agggctggac	1380
	tgcgaactgg	agaaggggag	agattttcaa	agagatacaa	gggaattggg	aggggtgcaa	1440
	aaagaggaga	gtaggaaaaa	tctgataatg	ctcaaaagga	aaaaaatct	ccgcagcgaa	1500
	acgacagctg	cggaaaaaaa	ccaccaatcc	catccaaatt	aacgcaaaaa	ccgtgatgcc	1560
	gactagaaaa	cttttatgag	agatcttggg	acttcttttt	gggggactat	ttttgtacag	1620
	agaaaacctg	agggcgggcg	ggagggcggg	ggaatcggac	catgtataga	tctggaggaa	1680
15	aaaaactacg	caaaactttt	ttttaagtt	ctagtggtag	gttaggcgct	tcgcaggag	1740
	ttcgcaaaag	tctttaccag	taatatcttag	agctagactc	cgggcgatga	aaaaaagtt	1800
	ttaatatttg	caagcaactt	ttgtacagta	tttatcgaga	taaacatggc	aatcaaatgt	1860
	ccattgttta	taagctgaga	atttgccaat	atttttcgag	gaaagggttc	ttgctgggtt	1920
	ttgattctgc	agcttaaat	taggaccgtt	acaaacaagg	aaggagtta	ttcggatttg	1980
20	aacatttttag	ttttaaaatt	gtacaaaagg	aaaacatgag	agcaagtact	ggcaagaccg	2040
	ttttcgtggt	cttgtttaag	gcaaacgttc	tagattgtac	taaattttta	acttactgtt	2100
	aaaggcaaaa	aaaaaatgtc	catgcaggtt	gatatcggtg	gtaattttata	atagcttttg	2160
	ttcaatccta	ccctttcatt	ttgttcacat	aaaaaatatg	gaattactgt	gtttgaaata	2220
	ttttcttatg	gtttgtaata	tttctgtaaa	ttgtgatatt	ttaagggtttt	tccccctttt	2280
	tattttccgt	agttgtattt	taaaagattc	ggctctgtta	ttggaatcag	gctgccgaga	2340
25	atccatgtat	atatttgaac	taataccatc	cttataacag	ctacattttc	aacttaagtt	2400
	tttactccat	tatgcacagt	ttgagataaa	taaatttttg	aatatggac	actgaaa	2457

<210> 6

<211> 2323

<212> DNA

<213> Rattus norvegicus

<400> 6

	gtgtttgcaa	aaagggaaaa	gtactttgct	gcctctttta	gactagggct	gggagaaaga	60
	agaggagaga	aaaagaaagg	agagaagttt	ggagcccag	gcttaagcct	ttccaaaaac	120
	taatcacaac	aatcgcggcg	gcccagggag	gagagcgact	gttttttcat	cccaattgca	180
	cttcgcccgt	ctcgagctcc	gcttcccccc	aactattctc	cgccagatct	ccgcgcaagg	240
35	ccgtgcacgc	cgacgacccc	gcccgcggcc	cctgcatccc	ggcccccgcg	cgccggcccc	300
	gcagtcccgg	ccgggcccag	ggtcggcgcc	cgccggcggg	ccgcgcccgc	gcccagcgcc	360
	cgcatgtata	acatgatgga	gacggagctg	aagccgccgg	gccctcagca	agcttcgggg	420
	ggcggcgggc	gaggaggcaa	cgccacggcg	gcggcgaccg	gcggcaacca	gaagaacagc	480
	ccggaccggc	tcaagaggcc	catgaatgcc	ttcatggtgt	ggtcccgggg	gcagcggcgt	540
40	aagatggccc	aggagaacct	caagatgcac	aactcggaga	tcagcaagcg	cctgggcgcc	600
	gagtggaaac	ttttgtcgga	gaccgagaag	cgcccggtta	tcgacgagcg	caagcggtcg	660
	cgcgctctgc	acatgaagga	gcacccggat	tataaatacc	ggccgcggcg	gaaaaccaag	720
	acgctcatga	agaaggataa	gtacacgctt	ccgggaggct	tgctggcccc	cgccgggaac	780
	agcatggcga	gcgggggttg	ggtggcgccc	ggcctgggtg	cgggcggtga	ccagcgcatg	840
	gacagctacg	cgcacatgaa	cggctggagc	aacggcagct	acagcatgat	gcaggagcag	900
45	ctgggctacc	cgcagcacc	ggcctcaac	gctcacggcg	cggcacagat	gcagccgatg	960
	caccgctacg	acgtcagcgc	cctgcagtac	aactccatga	ccagctcgca	gacctacatg	1020
	aacggctcgc	ccacctacag	catgtcctac	tcgcagcagg	gcacccccgg	tatggcgctg	1080
	ggctccatgg	gctctgtggt	caagtccgag	gccagttcca	gcccccccg	ggttacctct	1140
	tcctcccact	ccagggcgcc	ctgccaggcc	ggggacctcc	gggacatgat	cagcatgtac	1200
	ctccccggcg	ccgaggtgcc	ggagcccgct	gcgcccagta	gactgcacat	ggcccagcac	1260
50	taccagagcg	gcccgggtgc	cggcacggcc	attaacggca	cactgcccct	gtcgcacatg	1320
	tgagggccgg	accgcgaact	ggagaagggg	agagattttt	caaaaagata	caagggaatt	1380
	gggaggggtg	caaaagagga	gagtaagaaa	aatctgaatg	ctcaaaagga	aaaaaaaaat	1440
	ctcattaccc	gcagcaaaat	gacagctgcg	gaaaaaaacc	accaatccca	tccaaattaa	1500
	gtcaaaaacc	gtgatgccga	ctagaaaact	tttatgagag	atctggagga	aaaaaactac	1560
55	gcaaaaacttt	tttttaaggt	tctagtggta	cgttaggcgc	ttcgcaggga	gttctcaaaa	1620
	gtctttacca	gtaatattta	gaactagact	ccgggcgatg	aaaaaagttt	taatatattg	1680
	aagcaacttt	tgtacagtat	ttatcgagat	aaacatggca	atcaaatgtc	cattgtttat	1740

EP 2 881 461 A1

	aagctgagaa	tttgccaata	tttttcgagg	aaagggttct	tgctggggtt	tgattctgca	1800
	gcttaaatta	aggaccgtta	cagacaagga	aggaatttat	tcggatttga	acgttttagt	1860
	tttaaaattg	tacaaaagga	aaacatgaga	gcaagtactg	gcaagaccat	tttcgtgggtc	1920
	ttgtttaggg	caaacgttct	agattgtact	aaatttttaa	cttactgtta	aaggcaaaaa	1980
5	aaaaatgtcc	atgcaggttg	atatcgttgg	taatttataa	tagcttttgt	tcaatcccac	2040
	cctttttcatt	ttgttcacat	aaaaatatgg	aaattactgt	gtttgaaata	ttttcttatg	2100
	gtttgtaata	tttctgtaaa	ttgtgatatt	ttaaggtttt	ttcccccttt	tattttccgt	2160
	agttgtattt	taaaagattc	ggctgttatt	ggaaccaggc	tgccgagaa	ccatgtatat	2220
	atttgaacta	ataccatcct	tataacagtt	acgtttccaa	cttaagtttt	tactccatta	2280
10	tgcacagttt	gagataaata	aatttttgaa	atatggacac	tga		2323

<210> 7
 <211> 1411
 <212> DNA
 <213> Homo sapiens
 <400> 7

15	ccttcgcaag	ccctcatttc	accaggcccc	cggtctgggg	cgccttcctt	ccccatggcg	60
	ggacacctgg	cttcggattt	cgccttctcg	ccccctccag	gtggtggagg	tgatgggcca	120
	ggggggccgg	agccgggctg	ggttgatcct	cggacctggc	taagcttcca	aggccctcct	180
	ggagggccag	gaatcgggcc	gggggttggg	ccaggctctg	aggtgtgggg	gattccccca	240
	tgccccccgc	cgtatgagtt	ctgtgggggg	atggcgact	gtgggcccc	ggttgagtg	300
20	gggctagtgc	cccaaggcgg	cttggagacc	tctcagcctg	agggcgaaag	aggagtcggg	360
	gtggagagca	actccgatgg	ggcctccccg	gagccctgca	ccgtcaccac	tggtgccgtg	420
	aagctggaga	aggagaagct	ggagcaaaac	ccggaggagt	cccaggacat	caaagctctg	480
	cagaaagaac	tcgagcaatt	tgccaagctc	ctgaagcaga	agaggatcac	cctgggatata	540
	acacaggccg	atgtggggct	caccctgggg	gttctatttg	ggaaggtatt	cagccaaacg	600
	accatctgcc	gctttgaggg	tctgcagctt	agcttcaaga	acatgtgtaa	gctgcggccc	660
25	ttgctgcaga	agtgggtgga	ggaagctgac	aacaatgaaa	atcttcagga	gatatgcaaa	720
	gcagaaaccc	tcgtgcaggc	ccgaaagaga	aagcgaacca	gtatcgagaa	ccgagtgaga	780
	ggcaacctgg	agaatttggt	cctgcagtgc	ccgaaaccca	cactgcagca	gatcagccac	840
	atcgcccagc	agcttgggct	cgagaaggat	gtggtccgag	tgtggttctg	taaccggcgc	900
	cagaagggca	agcgatcaag	cagcgactat	gcacaacgag	aggattttga	ggctgctggg	960
30	tctcctttct	cagggggacc	agtgtccttt	cctctggccc	cagggcccca	ttttgggtacc	1020
	ccaggctatg	ggagccctca	cttacttgca	ctgtactcct	cggctccctt	ccctgagggg	1080
	gaagcctttc	cccctgtctc	cgtcaccact	ctgggctctc	ccatgcattc	aaactgaggt	1140
	gcctgcccct	ctaggaatgg	gggacagggg	gaggggagga	gctagggaaa	gaaaacctgg	1200
	agttttgtgc	agggtttttg	ggattaaagt	cttcattcac	taaggaagga	attgggaaca	1260
	caaagggtgg	gggcagggga	gtttggggca	actggttgga	gggaaggtga	agttcaatga	1320
35	tgctcttgat	tttaatccca	catcatgtat	caactttttc	ttaaataaag	aagcctggga	1380
	cacagtagat	agacacactt	aaaaaaaaaa	a			1411

<210> 8
 <211> 1346
 <212> DNA
 <213> Mus musculus
 <400> 8

40	aaccgtccct	aggtgagccg	tctttccacc	aggcccccgg	ctcgggggtg	ccaccttccc	60
	catggctgga	cacctggctt	cagacttcgc	cttctcacc	ccaccaggtg	gggtgatgg	120
	gtcagcaggg	ctggagccgg	gctgggtgga	tcttcgaacc	tggctaagct	tccaagggcc	180
45	tccaggtggg	cctggaatcg	gaccaggctc	agaggtattg	gggatctccc	catgtccgcc	240
	cgcatacgag	ttctgcgagg	ggatggcata	ctgtggacct	caggttgga	tgggcctagt	300
	cccccaagtt	ggcgtggaga	ctttgcagcc	tgagggccag	gcaggagcac	gagtggaaag	360
	caactcagag	ggaacctcct	ctgagccctg	tgccgaccgc	cccaatgccg	tgaagttgga	420
	gaaggtggaa	ccaactcccg	aggagtccca	ggacatgaaa	gccctgcaga	aggagctaga	480
	acagtttgcc	aagctgctga	agcagaagag	gatcaccttg	gggtacaccc	aggccgacgt	540
50	ggggctcacc	ctgggcgttc	tctttgaaa	ggtgttcagc	cagaccacca	tctgtcgctt	600
	cgaggccctg	cagctcagcc	ttaagaacat	gtgtaagctg	cggccccctg	tggagaagtg	660
	ggtggaggaa	gccgacaaca	atgagaacct	tcaggagata	tgcaaatcgg	agaccctgg	720
	gcaggcccg	aagagaaagc	gaactagcat	tgagaaccgt	gtgaggtgga	gtctggagac	780
	catgtttctg	aagtgcccga	agccctccct	acagcagatc	actcacatcg	ccaatcagct	840
55	tgggctagag	aaggatgtgg	ttcgagtatg	gttctgtaac	cggcgccaga	agggcaaaag	900
	atcaagtatt	gagtattccc	aacgagaaga	gtatgaggct	acagggacac	ctttcccagg	960
	gggggctgta	tcctttcctc	tgcccccagg	tccccacttt	ggcaccaccg	gctatggaag	1020

EP 2 881 461 A1

	ccccacttc	accacactct	actcagtccc	ttttcctgag	ggcgaggcct	ttccctctgt	1080
	tcccgtcact	gctctgggct	ctcccatgca	ttcaaactga	ggcaccagcc	ctccctgggg	1140
	atgctgtgag	ccaaggcaag	ggaggtagac	aagagaacct	ggagcttttg	ggttaaattc	1200
	ttttactgag	gagggattaa	aagcacaaca	ggggtggggg	gtgggatggg	gaaagaagct	1260
5	cagtgatgct	gttgatcagg	agcctggcct	gtctgtcact	catcattttg	ttcttaaata	1320
	aagactggga	cacacagtag	atagct				1346
	<210> 9						
	<211> 2949						
	<212> DNA						
10	<213> Homo sapiens						
	<400> 9						
	agtttcccga	ccagagagaa	cgaacgtgtc	tgcggggcgcg	cggggagcag	aggcggtggc	60
	gggcggcggc	ggcaccggga	gccgcgcagt	gacctcccc	cgccctctg	gccccacc	120
	ctcccaccg	cccgtaggcc	gcgcccattg	ccgcgcgcgc	tccacacaac	tcaccggagt	180
15	ccgcgccttg	cgccgcgcac	cagttcgcag	ctccgcgcga	cggcagccag	tctcacctgg	240
	cggcaccgcc	cgccaccgc	cccggccaca	gcccctgcgc	ccacggcagc	actcgaggcg	300
	accgcgacag	tggtagggga	cgctgctgag	tggaagagag	cgcagcccgg	ccaccggacc	360
	tacttactcg	ccttgctgat	tgtctatatt	tgcgtttaca	acttttctaa	gaacttttgt	420
	atacaaagga	actttttaaa	aaagacgctt	ccaagttata	tttaatccaa	agaagaagga	480
20	tctcggccaa	tttggggttt	tgggttttgg	cttcgtttct	tctcttcgtt	gactttgggg	540
	ttcaggtgcc	ccagctgctt	cgggctgccg	aggaccttct	gggcccccac	attaatgagg	600
	cagccacctg	gcgagtctga	catggctgtc	agcgacgcgc	tgctcccatc	tttctccacg	660
	ttcgcgtctg	gcccgcgcgg	aaggagagaag	acactgcgtc	aagcaggtgc	cccgaataac	720
	cgctggcggg	aggagctctc	ccacatgaag	cgacttcccc	cagtgtctcc	cgccgccccc	780
	tatgacctgg	cggcggcgac	cgtggccaca	gacctggaga	gcggcggagc	cggtgcggct	840
25	tgcggcggta	gcaacctggc	gcccctacct	cggagagaga	ccgaggagtt	caacgatctc	900
	ctggacctgg	actttattct	ctccaattcg	ctgacctatc	ctccggagtc	agtggccgcc	960
	accgtgtcct	cgtcagcgtc	agcctcctct	tcgtcgtcgc	cgtcagagcag	cgccctgtcc	1020
	agcgcgcctt	ccacctgcag	cttcacctat	ccgatccggg	ccgggaacga	cccgggcgtg	1080
	gcgcggggcg	gcacgggcgg	aggcctcctc	tatggcaggg	agtccgctcc	ccctccgacg	1140
	gctcccttca	acctggcggg	catcaacgac	gtgagccctt	cgggcggcct	cgtggccgag	1200
30	ctcctgcggc	cagaattgga	cccgggtgtac	attccgcgcg	agcagccgca	gcccgcaggt	1260
	ggcgggctga	tgggcaagtt	cgtgctgaag	gcgtcgtgta	gcgcccctgg	cagcgagtac	1320
	ggcagcccgt	cggatcatcag	cgtcagcaaa	ggcagccctg	acggcagcca	cccgggtggtg	1380
	gtggcgccct	acaacggcgg	gcccgcgcgc	acgtgcccc	agatcaagca	ggaggcggct	1440
	tcttcgtgca	cccacttggg	cgctggaccc	cctctcagca	atggccaccg	gccggctgca	1500
35	cacgacttcc	ccctggggcg	gcagctcccc	agcaggacta	ccccgaccct	gggtcttgag	1560
	gaagtgtctga	gcagcagggg	ctgtcacctt	gcccctgcgc	ttcctcccgg	cttccatccc	1620
	caccgggggc	ccaattaccc	atccttcctg	cccgatcaga	tgcagccgca	agtcccgcgc	1680
	ctccattacc	aagagctcat	gccacccggg	tccgtcatgc	cagaggagcc	caagccaaag	1740
	agggaagac	gatcgtggcc	ccggaaaagg	accgccacc	acacttgtga	ttacgcgggc	1800
	tgcggcaaaa	cctacacaaa	gagttcccat	ctcaaggcac	acctgcgaac	ccacacaggt	1860
40	gagaaacctt	accactgtga	ctgggacggc	tgtggatgga	aattcgcccg	ctcagatgaa	1920
	ctgaccaggc	actaccgtaa	acacacgggg	caccgcccgt	tccagtgcc	aaaatgcgac	1980
	cgagcatttt	ccaggtcggg	ccacctcgcc	ttacacatga	agaggcattt	ttaaatccca	2040
	gacagtggat	atgacccaca	ctgccagaag	agaattcagt	attttttact	tttcacactg	2100
	tcttcccgat	gagggaaagg	gcccagccag	aaagcaactac	aatcatgggt	aagttcccaa	2160
45	ctgagtcac	ttgtgagtgg	ataatcagga	aaaatgagga	atccaaaaga	caaaaatcaa	2220
	agaacagatg	gggtctgtga	ctggatcttc	tatcattcca	attctaaatc	cgacttgaat	2280
	attcctggac	ttacaaaatg	ccaagggggt	gactggaagt	tgtggatatc	agggatataa	2340
	ttatatccgt	gagttggggg	agggaagacc	agaattccct	tgaattgtgt	attgatgcaa	2400
	tataagcata	aaagatcacc	ttgtattctc	tttaccttct	aaaagccatt	attatgatgt	2460
	tagaagaaga	ggaagaaatt	caggtacaga	aaacatgttt	aaatagccta	aatgatgggt	2520
50	cttggtgagt	cttggttcta	aaggtaccaa	acaagggaagc	caaagttttc	aaactgctgc	2580
	atactttgac	aaggaaaatc	tatatattgt	ttccgatcaa	catttatgac	ctaagtccag	2640
	taatatacct	ggtttacttc	tttagcattt	ttatgcagac	agtctgttat	gcactgtggt	2700
	ttcagatgtg	caataatttg	tacaatggtt	tattcccaag	tatgccttaa	gcagaacaaa	2760
	tgtgtttttc	tatatagttc	cttgccttaa	taaatatgta	atataaattt	aagcaaacgt	2820
55	ctattttgta	tatttgtaaa	ctacaaagta	aaatgaacat	tttgtggagt	ttgtattttg	2880
	catactcaag	gtgagaatta	agtttttaaat	aaacctataa	tatttttatct	gaaaaaaaaa	2940
	aaaaaaaaaa						2949

<210> 10
 <211> 3057
 <212> DNA
 <213> Mus musculus
 <400> 10

```

5 agttccccgg ccaagagagc gagcgcggct ccggggcgcgc ggggagcaga ggcggtggcg 60
  ggcggcgggcg gcacccggag ccgcgcgagt cccctccccg cccctccagc ccccccacca 120
  gcaaccggcc cgtgaccgcg gcccatggcc gcgcgcaccc ggcacagtcc ccaggactcc 180
  gcaccccgcg ccaccgcca gctcgcagtt ccgcgcaccc gcggccattc tcacctggcg 240
  gcgcgcggcg cccaccgccc ggaccacagc cccgcgcgcg ccgacagcca cagtggccgc 300
10 gacaacgggtg ggggacactg ctgagtccaa gagcgtgcag cctggccatc ggacctactt 360
  atctgccttg ctgattgtct atttttataa gaggttttaa cttttctaag aatttttgta 420
  tacaaaggaa cttttttaaa gacatcgccg gtttatattg aatccaaaga agaaggatct 480
  cgggcaatct gggggttttg gtttgagggt ttgtttctaa agtttttaat cttcggtgac 540
  tttggggctc aggtacccct ctctctctt cggactccgg aggacctct ggccccccac 600
  attaattgagg cagccacctg gcgagctga catggctgtc agcgacgtc tgctcccgtc 660
15 cttctccacg ttgcgcgcg gcccgcggg aagggagaag acactgcgtc cagcaggtgc 720
  cccgactaac cgttggcggt aggaactctc tcacatgaag cgacttcccc cacttcccg 780
  ccgcccctac gacctggcgg cgacggtggc cacagacctg gagagtggcg gagctgggtc 840
  agcttgacgc agtaacaacc cggccctcct agcccgagg gagaccgagg agttcaacga 900
  cctcctggac ctgaccttta tcctttccaa ctgcctaacc caccaggaat cggtgggcgc 960
20 caccgtgacc acctcgcggt cagcttcctc ctgccttcc ccggcgagca gcggccctgc 1020
  cagcgcgccc tcacctgca gcttcagcta tcgatccgg gccgggggtg acccgggcgt 1080
  ggctgccagc aacacaggtg gagggctcct ctacagccga gaatctgcgc cacctcccac 1140
  ggcccccttc aacctggcgg acatcaatga cgtgagcccc tcgggcgggt tcgtggctga 1200
  gtcctgcgg ccggagttgg acccagtata cattccgcca cagcagcctc agccgccagg 1260
  tggcgggctg atgggcaagt ttgtgctgaa ggctctctg accaccctg gcagcgagta 1320
25 cagcagccct tcggtcatca gtgttagcaa aggaagcccc gacggcagcc acccgtggt 1380
  agtggcgccc tacagcggtg gcccgccgcg catgtgccc aagattaagc aagaggcggt 1440
  ccgctcctgc acggtcagcc ggtccctaga ggccatttg agcgtggac ccagctcag 1500
  caacggccac cggcccaaca cacacgactt cccctgggg cggcagctcc ccaccaggac 1560
  taccctaca ctgagtcctg aggaactgct gaacagcagg gactgtcacc ctggcctgcc 1620
  tcttccccca ggattccatc cccatccggg gcccaactac cctcctttcc tgccagacca 1680
30 gatgcagtc caagtcccct ctctccatta tcaagagctc atgccaccg gttcctgcct 1740
  gccagaggag cccaagccaa agaggggaag aaggtcgtgg ccccgaaaaa gaacagccac 1800
  ccacatttgt gactatgcag gctgtggcaa aacctatcc aagagttctc atctcaaggc 1860
  acacctgcga actcacacag gcgagaaaacc ttaccactgt gactgggacg gctgtgggtg 1920
  gaaattcgcc cgctccgatg aactgaccag gcaactaccg aaacacacag ggcaccggcc 1980
35 ctttcagtg cagaagtgtg acagggcctt ttccaggtcg gaccacctg ccttacacat 2040
  gaagaggcac ttttaaatcc cacgtagtgg atgtgaccca cactgccagg agagagagtt 2100
  cagtattttt ttttctaacc ttccacactg tcttcccacg aggggaggag cccagctggc 2160
  aagcgctaca atcatggtca agttcccagc aagtacgctt gtgaatggat aatcaggaga 2220
  aaggaagagt tcaagagaca aaacagaaat actaaaaaca aacaaacaaa aaaacaaaca 2280
  aaaaaaaca gaaaaaaaac tcacagaaca gatggggtct gatactggat ggtacttcta 2340
40 tcattccaat accaaatcca acttgaacat gcccggactt acaaaatgcc aaggggtgac 2400
  tggaagtttg tggatatcag ggtatacact aaatcagtga gcttgggggg agggaagacc 2460
  aggattccct tgaattgtgt ttcgatgatg caatacacac gtaaagatca ccttgtatgc 2520
  tctttgcctt cttaaaaaaa aaaaaagcca ttattgtgtc ggaggaagag gaagcgattc 2580
  aggtacagaa catgttctaa cagcctaaat gatggtgctt ggtgagtcgt ggttctaaag 2640
45 gtaccaaacy ggggagccaa agttctccaa ctgctgcata cttttgacaa ggaaaatcta 2700
  gttttgtctt ccgatctaca ttgatgacct aagccaggta aataagcctg gtttatttct 2760
  gtaacatttt tatgcagaca gtctgttatg cactgtggtt tcagatgtgc aataatttgt 2820
  acaatggttt attcccaagt atgcctttta gcagaacaaa tgtgtttttc tatatagttc 2880
  cttgccttaa taaatatgta atataaatat aagcaaaact ctattttgta tatttgtaaa 2940
  ctacaaagta aaaaaaatg aacattttgt ggagtttgta ttttgcatac tcaaggtgag 3000
50 aaataagttt taaataaacc tataatattt tatctgaacg acaaaaaaaa aaaaaaa 3057

```

<210> 11
 <211> 2393
 <212> DNA
 <213> Rattus norvegicus
 <400> 11

```

atcttcgttg acttcggggg ttgggtaccc ctctctcttc ttccgactcc ggaggacctt 60

```

EP 2 881 461 A1

	ctgggcccc	acattaatga	ggcagccacc	tggcgagctc	gacatggctg	tcagcgacgc	120
	tctgctccc	tccttctcca	cgttcgcgtc	cggcccgccg	ggaagggaga	agacactgcg	180
	tccagcaggt	gccccgacta	accgttgccg	agaggaactc	tctcacatga	agcgacttcc	240
	cccacttccc	ggccgccccct	acgacctggc	ggcgacgggtg	gccacagacc	tggaaagtgg	300
5	tggagctggt	gcagcttgca	gcagtaacaa	cccggcccta	cccgggaggg	agaccgagga	360
	gttcaacgat	ctcctggacc	tagactttat	cctttccaac	tcgctatccc	accaggaatc	420
	ggtggccgcc	accgtgacca	cctcggcgctc	agcttcatcc	tcgtcttccc	cagctagcag	480
	cggccctgcc	agcgcgccct	ccacctgcag	cttcagctat	ccgatccggg	ccgggggtga	540
	cccgggcggtg	gctgcgggca	acacaggtgg	agggctcctc	tacagccgag	aatctgcgcc	600
10	acctcccacg	gcccccttca	acctggcgga	catcaatgac	gtgagccccct	cgggcggtct	660
	cgtggctgag	ctcctgcggc	cggagtggga	cccagtatatac	attccgccac	agcagcctca	720
	gccgccaggt	ggcgggctga	tgggcaagtt	tgtgctgaag	gcgtctctga	gcacccctgg	780
	cagcgagtac	accagccctt	cgtcatcag	tgttagcaaa	ggaagcccg	accgagacca	840
	ccctgtggtg	gtggcgccct	acagcggtgg	cccgcgcgt	atgtgcccc	agattaagca	900
	agaggccgtc	ccgtcctgca	cggtcagccg	gtccctagag	gcccacttga	gcgtggacc	960
15	ccagctcagc	aacggccaca	ggcccaacac	acacgacttc	cccctggggc	ggcagctccc	1020
	caccaggact	acccctacac	tgagtcccga	ggaactgctg	aacagcaggg	actgtcaccc	1080
	tggcctgcct	cttccccccag	gattccatcc	ccatccgggg	cccagctacc	ctcctttcct	1140
	gccagaccag	atgcagtcgc	aagtcccctc	tctccattat	caagagctca	tgccaccggg	1200
	atcctgctcg	ccagaggagc	ccaagccaaa	gaggggaaga	aggtcttggc	cccggaaaag	1260
	aacagccacc	cacacttgtg	actatgcagg	ctgtggcaaa	acctatacga	agagttctca	1320
20	tctcaaggca	cacctgcgaa	ctcacacagg	cgagaaacct	taccactgtg	actgggacgg	1380
	ctgtgggtgg	aaattcgccc	gctcagatga	actgaccagg	cactaccgca	aacacaccgg	1440
	gcaccggccc	tttcagtgcc	agaagtgcga	cagggccttt	tccaggtcgg	accaccttgc	1500
	cttacacatg	aagaggcact	tttaaattcc	acatcgtgga	catgaccac	actgccagga	1560
	gagagttcag	tatttttttt	taacctttca	cactgtcttc	ccacgagggg	aggagcccag	1620
25	ctggcaagcg	ctacaatcat	ggtcaagttc	ccagcaagtc	agcttgtgaa	tggataatca	1680
	ggagaaagga	agagtccaag	ggacaaaaga	aaagaaaaga	aaaaaatact	aaaaaacaaa	1740
	caaacaaaaa	aaaaaaacaa	aagaaaaaaa	tcacagaaca	gatggggtct	gagactggat	1800
	cttctatcat	tccaatacca	aatccgactt	gaacaagact	ggacttacia	aatgccaaag	1860
	ggtgactgga	agttttgtgga	tatcagggtg	tacattaaat	cagtgcctg	gggggagggg	1920
	agaccagagt	tcccttgaat	tgtgcttcaa	tgatgcaata	tacatggaaa	gaccaccttg	1980
30	tatgctcttt	gccttctaaa	aagccattat	gacgtcagag	gaagagggaag	caattcaggt	2040
	acagaacgtg	ttctaatagc	ctaaccgatg	gtgcttggtg	agtcgtggtt	ctaaaggtac	2100
	caaacggggg	agccaaagtt	ctccaaactgc	tgcatacttt	gacaaggaaa	atctattttt	2160
	gtcttccgat	ctacatttat	gacctaagtc	aggtaaataa	gcctggttta	tttctgtaac	2220
	attttttatg	cgacagctct	gttatgcact	gtgttttcag	atgtgcaata	atttgtacaa	2280
	tggtttattc	ccaagtatgc	ctttaagcag	aacaaatgtg	tttttctata	tagttccttg	2340
35	ccttaataaa	tatgtaatat	aaatttataa	aaaaaaaaaa	aaaaaaaaaa	aaa	2393

<210> 12

<211> 4018

<212> DNA

<213> Homo sapiens

<400> 12

	caggcagcgc	tgcgtcctgc	tgcgcacgtg	ggaagccctg	gccccggcca	cccccgcat	60
	gccgcgcgct	ccccgctgcc	gagccgtgcg	ctccctgctg	cgcagccact	accgcgaggt	120
	gctgccgctg	gccacgttcg	tgcggcgccct	ggggcccccag	ggctggcggc	tgggtgcagcg	180
	cggggacccg	gcggctttcc	gcgcgctggt	ggcccagtg	ctggtgtgcg	tgccctggga	240
45	cgcacggccg	ccccccgccc	ccccctcctt	ccgccaggtg	tcctgcctga	aggagctggt	300
	ggcccagagt	ctgcagaggc	tgtgcgagcg	cggcgcgaa	aacgtgctgg	ccttcggctt	360
	cgcgctgctg	gacggggccc	gcgggggccc	ccccgagggc	ttaccacca	gcgtgcgcag	420
	ctacctgccc	aacacgggtg	ccgacgcact	gcgggggagc	ggggcggtgg	ggctgctgct	480
	gcgcgcgctg	ggcgacgacg	tgtgtgttca	cctgctggca	cgctgcgcgc	tctttgtgct	540
	ggtggctccc	agctgcgcct	accaggtgtg	cgggcccggc	ctgtaccagc	tcggcgctgc	600
50	cactcaggcc	cggccccccg	cacacgctag	tggaccccga	aggcgtctgg	gatgcgaacg	660
	ggcctggaac	catagcgtca	gggagggccg	ggtccccctg	ggcctgccag	ccccgggtgc	720
	gaggaggcgc	gggggcagtg	ccagccgaag	tctgcccgtt	cccaagaggc	ccaggcgtgg	780
	gcctgccctt	gacgcggagc	ggacgcccgt	tgggcagggg	tcctggggcc	accgggagca	840
	gacgcgtgga	ccgagtgacc	gtggtttctg	tgtggtgtca	cctgccagac	ccggcgaaga	900
	agccacctct	ttggagggtg	cgctctctgg	cacgcgccac	tcccacccat	ccgtgggccc	960
55	ccagcaccac	gcggggcccc	catccacatc	gcggccacca	cgtccctggg	acacgccttg	1020
	tcccccggtg	tacgccgaga	ccaagcactt	cctctactcc	tcaggcgaca	aggagcagct	1080

EP 2 881 461 A1

	gcggccctcc	ttctactca	gctctctgag	gccagcctg	actggcgctc	ggaggctcgt	1140
	ggagaccatc	tttctgggtt	ccaggccctg	gatgccaggg	actccccgca	ggttgccccg	1200
	cctgccccag	cgctactggc	aatgcgggcc	cctgtttctg	gagctgcttg	ggaaccacgc	1260
	gcagtgcccc	tacgggggtgc	tctcaagac	gcactgcccc	ctgcgagctg	cggtcaccac	1320
5	agcagccggt	gtctgtgccc	gggagaagcc	ccagggtctc	gtggcgggcc	ccgaggagga	1380
	ggacacagac	ccccgtcgcc	tggcgagctc	gctccggcag	cacagcagcc	cctggcaggt	1440
	gtacggcttc	gtgcgggcct	gcctgcggcg	gctggtgccc	ccaggcctct	ggggctccag	1500
	gcacaacgaa	cgccgcttcc	tcaggaacac	caagaagttc	atctccctgg	ggaagcatgc	1560
	caagctctcg	ctgcaggagc	tgacgtggaa	gatgagcgtg	cgggactgcg	cttggtgctg	1620
10	caggagccca	ggggttggct	gtgttccggc	cgagagcagc	cgtctgcgtg	aggagatcct	1680
	ggccaagttc	ctgcaactggc	tgatgagtgt	gtacgtcgctc	gagctgctca	ggtctttctt	1740
	ttatgtcacg	gagaccacgt	ttcaaaagaa	caggctcttt	ttctaccgga	agagtgtctg	1800
	gagcaagtgt	caaagcattg	gaatcagaca	gcacttgaag	agggtgcagc	cttcgggagc	1860
	gtcggaagca	gaggtcaggc	agcatcgagg	agccaggccc	gccctgctga	cgtccagact	1920
	ccgcttcac	cccaagcctg	acgggctgcg	gccgattgtg	aacatggact	acgtcgtggg	1980
15	agccagaacg	ttccgcagag	aaaagagggc	cgagcgtctc	acctcgaggg	tgaaggcact	2040
	gttcagcgtg	ctcaactacg	agcggcgcg	gcgccccggc	ctcctggggc	cctctgtgct	2100
	gggcctggac	gatatccaca	gggcctggcg	caccttcgtg	ctgcgtgtgc	gggcccagga	2160
	cccgcgcct	gagctgtact	ttgtcaaggt	ggatgtgacg	ggcgcgtagc	acaccatccc	2220
	ccaggacagg	ctcacggagg	tcacgcgcag	catcatcaaa	ccccagaaca	cgtactgctg	2280
	gcgtcgggtat	gccgtggtcc	agaaggccgc	ccatgggcac	gtccgcaagg	ccttcaagag	2340
20	ccacgtctct	accttgacag	acctccagcc	gtacatgcga	cagttcgtgg	ctcacctgca	2400
	ggagaccagc	ccgctgaggg	atgccgtcgt	catcgagcag	agctcctccc	tgaatgaggg	2460
	cagcagtggc	ctcttcgacg	tcttccctacg	cttcatgtgc	caccacgccc	tgcgcatcag	2520
	gggcaagtcc	tacgtccagt	gccaggggat	ccgcagggc	tccatcctct	ccacgctgct	2580
	ctgcagcctg	tgctacggcg	acatggagaa	caagctgttt	gcggggattc	ggcgggacgg	2640
25	gctgctcctg	cgtttggtgg	atgatttctt	gttgggtgaca	cctcacctca	cccacgcgaa	2700
	aaccttcctc	aggaccctgg	tccgaggtgt	ccctgagtat	ggctgctggg	tgaacttgcc	2760
	gaagacagtg	gtgaacttcc	ctgtagaaga	cgaggccctg	ggtggcacgg	cttttgttca	2820
	gatgccggcc	cacggcctat	tcccctgggtg	cggcctgctg	ctggataccc	ggaccctgga	2880
	ggtgcagagc	gactactcca	gctatgcccg	gacctccatc	agagccagtc	tcaccttcaa	2940
	ccgcggcttc	aaggctggga	ggaacatgcg	tcgcaaaactc	tttggggctc	tgcggtgtaa	3000
30	gtgtcacagc	ctgtttctgg	atttgcaggt	gaacagcctc	cagacggtgt	gcaccaacat	3060
	ctacaagatc	ctcctgctgc	aggcgtacag	gtttcacgca	tgtgtgctgc	agctccatt	3120
	tcacagcaaa	gttttgaaga	acccacatt	tttccctgccc	gtcatctctg	acacggcctc	3180
	cctctgctac	tccatcctga	aagccaagaa	cgaggggatg	tcgctggggg	ccaagggcgc	3240
	cgccggccct	gtgccctccg	aggccgtgca	gtggctgtgc	caccaagcat	tccctgctcaa	3300
	gctgactcga	caccgtgtca	cctacgtgcc	actcctgggg	tcactcagga	cagcccagac	3360
35	gcagctgagt	cggaagctcc	cggggacgac	gctgactgcc	ctggaggccg	cagccaaccc	3420
	ggcactgccc	tcagacttca	agaccatcct	ggactgatgg	ccaccgccc	acagccaggc	3480
	cgagagcaga	caccagcagc	cctgtcacgc	cggtctctac	gtcccaggga	gggagggggc	3540
	gcccacaccc	aggcccgcac	cgctgggagt	ctgaggcctg	agtgagtgtt	tggccgaggc	3600
	ctgcatgtcc	ggctgaaggc	tgagtgtccg	gctgaggcct	gagcgagtgt	ccagccaagg	3660
40	gtcaggtgtc	cagcacacct	gccgtcttca	cttcccaca	ggctggcgct	cggctccacc	3720
	ccagggccag	cttttccctca	ccaggagccc	ggcttccact	ccccacatag	gaatagtcca	3780
	tcccagatt	cgccattgtt	caccctctgc	cctgccctcc	tttgccttcc	acccccacca	3840
	tccaggtgga	gaccctgaga	aggaccctgg	gagctctggg	aatttgaggt	gaccaaaggt	3900
	gtgccctgta	cacaggcgag	gaccctgcac	ctggatgggg	gtccctgtgg	gtcaaattgg	3960
45	ggggaggtgc	tgtgggagta	aaatactgaa	tatatgagtt	tttcagtttt	gaaaaaaa	4018
	<210> 13						
	<211> 4237						
	<212> DNA						
	<213> Mus musculus						
	<400> 13						
50	ggttcccgca	cgtgggaggg	ccatcccgcc	cttgagcaca	atgaccgcgc	ctcctcgttg	60
	cccccggggtg	cgctctctgc	tgccgagccg	ataccgggag	gtgtggccgc	tggcaacctt	120
	tgtgcgggcg	ctggggcccc	agggcagggc	gcttgtgcaa	cccggggacc	cgaagatcta	180
	ccgcactttt	gttgcctaat	gcctagtgtg	catgcactgg	ggctcacagc	ctccacctgc	240
	cgacctttcc	ttccaccagg	tgtcatccct	gaaagagctg	gtggccaggg	ttgtgcagag	300
55	actctgcgag	cgcaacgaga	gaaacgtgct	ggcttttggc	tttgagctgc	ttaacgaggg	360
	cagaggcggg	cctcccatgg	ccttacttag	tagcgtgcgt	agctacttgc	ccaacactgt	420
	tattgagacc	ctgcgtgtca	gtgggtgcag	gatgctactg	ttgagccgag	tgggcgacga	480

EP 2 881 461 A1

5 cctgctgggtc tacctgctgg cacactgtgc tctttatctt ctggtgcccc ccagctgtgc 540
 ctaccagggtg tgtgggtctc cctgtacca aatttgtgcc accacggata tctggccctc 600
 tgtgtccgct agttacaggc ccacccgacc cgtgggcagg aatttacta accttaggtt 660
 cttacaacag atcaagagca gtatgcgcca ggaagcaccg aaacccctgg ccttgccatc 720
 10 ctaggttaca aagaggcatc tgagtctcac cagtacaagt gtgccttcag ctaagaaggc 780
 cagatgctat cctgtcccga gagtggagga gggacccac aggcaggtgc taccaccccc 840
 atcaggcaaa tcatgggtgc caagtccctgc tcgggtcccc gaggtgccta ctgcagagaa 900
 agatttgtct tctaaaggaa aggtgtctga cctgagtctc tctgggtcgg tgtgctgtaa 960
 acacaagccc agctccacat ctctgctgtc accaccccg caaaatgcct ttcagctcag 1020
 gccatttatt gagaccagac atttccttta ctccagggga gatggccaag agcgtctaaa 1080
 15 cccctcatte ctactcagca acctccagcc taacttgact ggggccagga gactggtgga 1140
 gatcatcttt ctgggctcaa ggcctaggac atcaggacca ctctgcagga cacaccgtct 1200
 atcgctcga tactggcaga tgcggccctt gttccaacag ctgctggtga taccagcaga 1260
 gtgccaatat gtcagactcc tcaggtcaca ttgcaggttt cgaacagcaa accaacagggt 1320
 gacagatgcc ttgaacacca gccacccgca cctcatggat ttgctccgcc tgcacagcag 1380
 20 tccctggcag gtatatggtt ttcttcgggc ctgtctctgc aaggtggtgt ctgctagtct 1440
 ctgggggtacc aggcacaatg agcggcgtt ctttaagaac ttaaagaagt tcatctcggt 1500
 ggggaaatac ggcaagctat cactgcagga actgatgtgg aagatgaaag tagaggattg 1560
 ccactggctc cgcagcagcc cggggaagga ccgtgtcccc gctgcagagc accgtctgag 1620
 ggagaggatc ctggctacgt tcctgttctg gctgtaggac acatacgtgg tacagctgct 1680
 taggtcattc ttttacctca cagagagcac attccagaag aacaggctct tcttctaccg 1740
 25 taagagtgtg tggagcaagc tgcagagcat tggagttagg caacaccttg agagagtgcg 1800
 gctacgggag ctgtcacaag aggaggtcag gcatcaccag gacacctggc tagccatgcc 1860
 catctgcaga ctgcgttca tcccaagcc caacggcctg cggccattg tgaacatgag 1920
 ttatagcatg ggtaccagag ctttgggcag aaggaagcag gccagcatt tcacccagcg 1980
 tctcaagact ctcttcagca tgctcaacta tgagcggaca aaacatcctc accttatggg 2040
 gtcttctgta ctgggtatga atgacatcta caggacctgg cgggccttg tgctgctgt 2100
 30 gctgctctg gaccagacac ccaggatgta ctttgttaag gcagatgta ccggggccta 2160
 tgatgccatc ccccagggtg agctggtgga ggttgttgcc aatatgatca ggcactcgga 2220
 gagcacgtac tgtatccgcc agtatgcagt ggtccggaga gatagccaag gccaaagtcca 2280
 caagtccctt aggagacagg tcaccaccct ctctgacctc cagccataca tggggcagtt 2340
 ccttaagcat ctgcaggatt cagatgccag tgcactgagg aactccgttg tcacgagca 2400
 gagcatctct atgaatgaga gcagcagcag cctgtttgac ttcttcctgc acttcctgcg 2460
 35 tcacagtgtc gtaaagattg gtgacaggtg ctatacgcag tgccagggca tccccaggg 2520
 ctccagccta tccaccctgc tctgcagtct gtgtttcgga gacatggaga acaagctgtt 2580
 tgctgaggtg cagcgggatg ggttgccttt acgtttgtt gatgactttc tgttggctgac 2640
 gcctcacttg gaccaagcaa aaaccttct cagcaccctg gtccatggcg tctctgagta 2700
 tgggtgcatg ataaacttgc agaagacagt ggtgaacttc cctgtggagc ctggtaccct 2760
 40 ggggtggtgca gctccatacc agctgcctgc tcaactgcctg tttccctggg gtggcttgc 2820
 gctggacact cagactttgg aggtgttctg tgactactca gggtatgcc agacctcaat 2880
 taagacgagc ctacacctcc agagtgtctt caaagctggg aagaccatgc ggaacaagct 2940
 cctgtcgggtc ttgcggttga agtgtcacgg tctatttcta gacttgcagg tgaacagcct 3000
 ccagacagtc tgcataata tatacaagat cttcctgctt caggcctaca ggttccatgc 3060
 45 atgtgtgatt cagcttccct ttgaccagcg tgttaggaag aacctcacat tcttctggg 3120
 catcatctcc agccaagcat cctgtgcta tgctatcctg aaggtcaaga atccaggaat 3180
 gacactaaag gcctctggct ccttctctcc tgaagccgca cattggctct gctaccaggc 3240
 cttcctgctc aagctggctg ctcatctgt catctacaaa tgtctcctgg gacctctgag 3300
 gacagcccaa aaactgctgt gccggaagct ccagaggcg acaatgacca tccttaaagc 3360
 50 tgcagctgac ccagccctaa gcacagactt tcagaccatt ttggactaac cctgtctcct 3420
 tccgctagat gaacatgggc attgtagcct cagcactcct ggatccacgt cacaagaggg 3480
 actggtcagt tgtgaggcta ggtcatcctc caaacctctg tgtcatgggt ggtatgggag 3540
 attgtcccag tgccttgttt cctgtaacag gcttgatttc tttcctgatg cctcaggga 3600
 ggcagatcct atccctttta gtggcaggga tccactagca ccagcacatg aggagtgcac 3660
 ccagtgcaca tgggcactgg gacagtggac aggtgtgaga ttctggggc ctggagtctt 3720
 55 ttcacaccta accatggagc ctgtcccagt acatcagagt gcctcgaga tgaaaaagga 3780
 catcgagcca gtgacctaaa ttacagcctg aatatactct gaattcatgt gactgcctta 3840
 gctacttctc tactgctgtg tagtaaaaca ccaagccaac ttataaaaagc aggattttcc 3900
 tactggagca gcagctgaga gtttacatct tgatccataa gcacaaaagc acaagacaga 3960
 gagagagaga gagagagaga gagagagaga gagagagaga gagagagtca 4020
 gtcagtgcag ctacaaaata actaagaaag gtgaagggtg atgaagtcca cagggatcac 4080
 60 gctagggatg ttccatgcct tctctgaagc taagattcct tggcagcgtt tgacagtaac 4140
 catagtgggt acctactgag atcactataa agataaaaata gggggaagcg tatttgtact 4200
 gaactggaaa aacatacaaa taaagagtaa atcatgg 4237

<210> 14
 <211> 3378
 <212> DNA
 <213> *Rattus norvegicus*
 <400> 14

5	atgccccgcg	ctcctcgttg	ccccgcgctg	cgctctctac	tgcgcagccg	atatcgggag	60
	gtgtggccgc	tggcgacctt	tgtgcggcgc	ctggggcctt	agggcagtcg	gcttgtgcaa	120
	cccggggacc	cgaaggtctt	ccgcacgttg	gttgcccagt	gcctagtgtg	cgtgcccttg	180
	ggctcacagc	cgccacctgc	tgacctttcc	ttccaccagg	tgtcatccct	gaaagagctg	240
10	gtgtccagg	ttgtgcagaa	actttgcgag	cgcggtgaga	ggaatgtgct	ggcttttggc	300
	tttgactgc	ttaacggggc	cagaggtggg	cctcccatgg	ccttcacgac	cagcgtgcat	360
	agctacttgc	ccaactcgtt	tactgagtc	ctgtgtgtca	gtggtgcatg	gatgctactg	420
	ttgagccgag	tgggcgacga	cctgctggtc	tacctgctgt	cgcactgtgc	gctctacctg	480
	ctggtgcccc	ccagctgtgc	ctaccagggt	tgcgggtcac	ccctgtacca	aatttgtgcc	540
	accacggata	cctggtcctc	tgtgcccgtc	ggttacaggc	ccactcgacc	cgtgggcggg	600
15	aatttcacta	accttgggtc	cgcacaccag	atcaaaaaca	gtggtcacca	ggaagcacca	660
	aaaccccagg	ccttgccatc	acgaggtacg	aagaggcttc	tgagtctcac	cagtacaaac	720
	gtgccttcag	ctaagaaggc	caggtttgaa	cctgccctga	gagtgataa	gggacccac	780
	aggcaggtgg	taccaacccc	atcaggcaaa	acatgggccc	caagtccctg	tgcgtccccc	840
	aaggtgcctc	ctgcagcgaa	aaacttgtct	ttgaaaggaa	aggcatctga	cccagatctc	900
20	tctgggtcgg	tgtgctgtaa	acacaagccc	agctcctcgt	ccctgctgtc	atcaccaccc	960
	caagatgctg	aaaagctcag	gccattcact	gagaccagac	atttccttta	ctccagggga	1020
	ggtggccaag	aggagctaaa	tccctcattc	ctactcaaca	gcctcccgc	tagcttgacc	1080
	ggggccagg	gactggtgga	gatcatcttt	ctgggtcaa	ggcctaggac	atcaggacca	1140
	ttctgcagga	cccgccgcct	gccccgtcga	tactggcaga	tgcgaccct	attccagcag	1200
	ctgctcatga	accacgcaaa	gtgccaatat	gtcagattcc	tccggtcgca	ctgcagattt	1260
25	cgaacagcaa	accagcgggt	gccggatgcc	atggacacca	gccatccca	cctcacaggt	1320
	ttgctccggt	tacacagcag	cccctggcag	gtatacggct	ttcttcgggc	ctgcctccgc	1380
	gagctggtgc	ctgccggtct	ctggggcacc	aggcacaatg	agcgcgcgtt	cttaaagaac	1440
	gtgaagaagt	tcatctcgtt	ggggaagtac	gccaaagctat	ccctgcagga	actgatgtgg	1500
	agggtgaaag	tggaggactg	ccactggctc	cgcagcagcc	cagagaagga	actgtccct	1560
	gccgcagagc	accgtctgag	ggagaggatc	cttgccatgt	tcctgttctg	gctaattggc	1620
30	acatatgtgg	tacagctgct	gaggtcattc	ttctacatca	cagagaccac	gttccagaag	1680
	aaccgccttt	tcttctaccg	taagagtgtg	tggagcaagc	tgcagagcat	tggaatcagg	1740
	caacagcttg	agagagttca	gctacgggaa	ctgtcacaag	aggaggtcaa	gcatcaccag	1800
	gacacttggc	tggccatgcc	tatctgcaga	ttgcgcttca	tccccaagct	caatggtctc	1860
	cggcccattg	tgaacatgag	ttatggcatg	gacaccagag	cttttgcaa	aaagaagcag	1920
35	acccagtgtt	tactcagag	tctcaagact	ttgttcagcg	tgtcaacta	cgagcggacc	1980
	aaacatccta	accttatggg	tgttccagta	ctgggtacga	gtgacagcta	caggatctgg	2040
	cggaccttcg	tgctgcgtgt	gcgtgctctg	gaccagacac	ccaggatgta	ctttgttaag	2100
	gcagatgtga	caggggccta	tgatgccatc	ccccaggaca	agctcgtgga	aattgtcgcc	2160
	aatataatca	ggcgctcaga	gagcatgtac	tgtatccgcc	agtatgcagt	ggttcagaaa	2220
	gatagccaag	gccaagtcca	caagtccttc	aggagacagg	tctccaccct	ctctgacctc	2280
40	cagccataca	tgggccagtt	caccaagcat	ctgcaggact	cagatgccag	tgcactgagg	2340
	aactctgttg	tcatcgagca	gagcatctcc	atgaatgaga	ctggcagtag	cctgctccac	2400
	ttcttcctgc	gctttgtccg	tcacagtgtc	gtgaagatcg	atggcaggtt	ctatgtgcaa	2460
	tgccagggca	tcccccagg	ctccagcctg	tccaccctgc	tctgcagtct	gtgtttcgga	2520
	gacatggaga	acaagctgtt	tgccgaggtg	cagcaggacg	gcttgctttt	acgttttgtc	2580
45	gatgactttc	tgttggtgac	acctcacctg	gcccattgca	aagcctttct	cagcaccctg	2640
	gtccatggcg	tgcccagta	tggctgcagc	ataaacttgc	agaagacagt	ggtgaacttc	2700
	cctgtggaga	ccggcgccct	gggaggtgca	gccccgcacc	agctgcctgc	tactgcctg	2760
	tttccctggt	gtggcttact	gctggacact	cggacttttg	aagtattctg	tgactactca	2820
	ggttacggac	ggacctcaat	taagatgagc	ctcaccttcc	aggggtgtctc	cagggccggg	2880
	aagaccatgc	ggtacaagct	cttgtcagtc	ttgcggttga	agtgtcatgg	tctgtttcta	2940
50	gacttgcagg	tgaacagcct	gcagacagtc	tgcatacata	tatacaagat	cttcctgctt	3000
	caggcctaca	ggttccatgc	atgtgtgatt	cggcttccct	ttggccagca	tgtaggaag	3060
	aaccatgcat	tctttctggg	catcatctcc	aacctagcat	cctgctgcta	cgccatcctg	3120
	aaggtcaaga	atccaggagt	gtcactaagg	gccaagggtg	cccctggctc	ctttccgccc	3180
	gaggccacac	gttggctctg	ctaccaagcc	ttcctgctca	agctggctgc	tcatttctgtc	3240
	acctacaagt	gtctcctggg	acctcttagg	acagcccaaa	aacagctgtg	ccggaagctc	3300
55	ccagaggcaa	caatgaccct	ccttaagact	gcagctgacc	cagccctaag	cacagatttt	3360
	cagaccattt	tggactaa					3378

<210> 15
 <211> 1903
 <212> DNA
 <213> Homo sapiens
 <400> 15

```

5  cggcggtccccc gggggcccaact cccgagcgca gggcgggcagc caggcgggcg gcgcggcgcg 60
   ggccggcagg aagcgtattc tgggcacggg ggcggggcg ggccggctgc gccgagcggc 120
   agtgggtggga taccacccaa ggcctcgcg ggcgcggccc gtcgaggggc gggcgggcg 180
   gtagccactg ggccgtcgaa gagcgagga ggcgggtggg ccggggccggg ccgcgcggcg 240
10  cagccatgcc tggctttacg tgctgcgtgc caggctgcta caacaactcg caccgggaca 300
   aggcgctgca cttctacacg tttccaaagg acgctgagtt gcggcgccctc tggctcaaga 360
   acgtgtcgcg tgccggcgctc agtgggtgct tctccacctt ccagcccacc acaggccacc 420
   gtctctgcag cgttcaactt cagggcgggc gcaagacctt cacggtagcg gtccccacca 480
   tcttcccgcg gcgcggcgctc aatgagcgca agtagcgcg cagaccgcgt ggggcgcggg 540
   ccgcccgcgg caggcagcag cagcaacagc agcagcagca gcaacagcag caacagcagc 600
15  agcagcagca acagcagcag cagcagcagc agcagcagca gtcctcacc tctgcctcca 660
   ctgcccagac tgcccagctg cagccgaacc tggatatctg ttcgcgggcc gtgcttctca 720
   cccttcaggc cactgtagac agcagtcagg ctccgggatc cgtacagccg gcgcccata 780
   ctcccactgg agaagacgtg aagcccacgt atctcacagt gcaagtggag tttgcagccg 840
   cagagggcgcg agccgctgcg gccgcccgcgt cggagttaca ggctgctacc gcagggctgg 900
   aggctgcccga gtgccctatg ggcccccagt tgggtgggtgg aggggaagag ggcttccctg 960
20  atactggctc cgaccattcg tactccttgt cgtcaggcac cacggaggag gagctcctgc 1020
   gcaagctgaa tgagcagcgg gacatcctgg ctctgatgga agtgaagatg aaagagatga 1080
   aaggcagcat tcgccacctg cgtctcactg aggccaaagt gcgcgaagaa ctgctgaga 1140
   aggatcggtc gcttgccatg gctgtcatcc gcaagaagca cggaatgtga actggtgccc 1200
   cggcagcctg ctggactccc agaccccatc cagccagggg accgcaggcc attgttgaac 1260
25  tcctctatac tcctgggcac tgggtgacag tactgaggct taaggcagct ggactctctt 1320
   gctggtgacc tggcatcctc aattgtttcc tctgaagtg gaagctgggg ccttagactc 1380
   tgccctggtg acaccagcaa ttatgacttt gtctaccctt cctccccagt tattgttgca 1440
   gattctggtt aagcagaggc ttcagaacca ctgaacttga aacttaccct ctagggatgc 1500
   aggtgggatg tccagggact ataggtttgg gaaaaccata ccttaagggt ggctcagcag 1560
   cagacaactc taatgtgtgt agtgataaga gattcaagta acatcagttc tcctcctttt 1620
30  catgcttttc cttcccaggt gcagcctgtg attctgatgg ggactggtaa atctgtgcct 1680
   ctgcctccta ggacttatct tcccaggagg ccatttataa ggggatcttg atgacctgct 1740
   gatggagatc cagcttgcca gggacttagg tttatcctgt tttgtttgct actggttaca 1800
   aattctatct tctgtacaat tagtcagact aaagttttca ctgtgtttgt ttggcaaaac 1860
   aaattaaaca aaaagtaagg tttttaaaaa aaaaaaaaaa aaa 1903

```

<210> 16
 <211> 1832
 <212> DNA
 <213> Mus musculus
 <400> 16

```

40  gaagcgcagg cggacggccg ggtgggtagc agcgggcgcg gcggtccgca accatattct 60
   gggcacgggg cctcggcccg ggacgactgc gccggggcg aatagtgaaga ggcctctgag 120
   agcctcgcg ggcggcgccc gtcgaggagc tgagacaggg gccagaccgg gccgtcgaag 180
   agctcgagag gccgggtggg cgggcccgcg gtcgcagcca tgcctggctt tacgtgctgc 240
   gttccgggct gctacaacaa ttcacaccgg gacaaggcgc tgcacttcta cacgtttccc 300
45  aaggacgctg agttgcggcg cctctggctc aagaacgtgt cccgtgctgg cgtcagtgag 360
   tgcttctcca ccttccaacc caccaccggc caccgtctct gcagcgtcca ctttcagggg 420
   ggccgcaaga cctacacggt gcgcgttccc accattttcc cgtgcgtgg cgtcaatgag 480
   cgcaaagtag ctcgagagac tgcgggagct gcggcagccc gccgtaggca gcagcagcag 540
   caacaacaac agcagcagca gcaacagcag cagctgcaac agcagcagcc gtctccgtcc 600
   tcctccactg ccagaccac ccagttgcag ccgaacctgg tgtctgcctc tgcagctgtg 660
50  cttcttacgc ttcaggccgc cgtagacagc aaccaggctc cgggatccgt ggttcccgtg 720
   tccacgactc cctcgggaga tgatgtgaag cccatcgacc tcacagtga agtcgagttt 780
   gcagctgctg aaggggcagc cgccgctgcc gccgcctcag agctagaggc tgctacggct 840
   gggctggagg ccgctgagtg cactctgggc cctcagctgg tgggtggtag ggaagaggag 900
   ttccctgaca ctggctctga ccactcgtae tcttgtcct cgggtaccac ggaggaggag 960
55  ctctgcgca agctgaacga gcagcgggac atcttggccc tgatggaagt gaagatgaag 1020
   gagatgaagg gtagcatccg ccatctgcgt ctaccgagg ccaagctccg tgaagaactt 1080
   cgagagaagg atcgtctgct tgccatggct gtcacccgta agaagcacgg catgtgaatg 1140

```

EP 2 881 461 A1

```

gttcccccca gaaacctgca gaattcgtga ctccctccag cccaaggaat cctcaggcaa 1200
atgttgact cccagctatt cctgttgaca gtgccgaggt ttaggacagc gggactccag 1260
ttggtcagtt ggcaccttct ttcgtctcct cgtgaagtaa gagttgggga cttcagaatc 1320
5  tggtgacacc agcagttatg actttgtctc tcaactccca gtttatgttg cagattctgg 1380
ttatacacag gcttcagaac cactgaactt ggaacttacc ctggaggggg tgcagatgga 1440
actcttaagg gactgtgggt ttgaggaaac cacttcttca ggttggccag caatcagaga 1500
cagctttgct gtgtgtagtg ataagagatc tcagtaacat cgtttctcct ttccatgcta 1560
cccggttcag gtgcagtctg tgattctgat ggggactagc tgatctgtgc ctctgtctct 1620
taggacctct ctaccagaa ggtcatttat gagagggtc tgggtgactt gctgatggag 1680
10 atccagctca ccagggactt aggtttatct cgttatgttt gctactggtt acaaattcta 1740
ttttctgtac aattagactg aagttttcac tgtttggcaa aacaaattaa aaaaaaaagt 1800
aaggttttta aaaaaaaaaa aaaaaggcca ca 1832

<210> 17
<211> 55
15 <212> DNA
<213> Escherichia coli
<400> 17
tctagagcgg cgcgccggcg ggtcgccacc atgagtgtgg atccagcttg tcccc 55

<210> 18
20 <211> 36
<212> DNA
<213> Escherichia coli
<400> 18
catgcaacct gaagacgtgt gaagactagt atcgat 36

25 <210> 19
<211> 51
<212> DNA
<213> Escherichia coli
<400> 19
30 tctagagcgg cgcgccggcg ggtcgccacc atggctgtca gcgacgcgct g 51

<210> 20
<211> 46
<212> DNA
35 <213> Escherichia coli
<400> 20
ccacctogcc ttacacatga agaggcattt ttaaaagctt atcgat 46

<210> 21
40 <211> 50
<212> DNA
<213> Escherichia coli
<400> 21
tctagaggat ccccggcggg tcgccaccat ggcggccgcg ggaattcgat 50

45 <210> 22
<211> 39
<212> DNA
<213> Escherichia coli
<400> 22
ggcacactgc ccctctcaca catgtgaaag cttatcgat 39

50 <210> 23
<211> 51
<212> DNA
<213> Escherichia coli
<400> 23
55 tctagagcgg cgcgccggcg ggtcgccacc atggcgggac acctggcttc g 51

<210> 24

```

<211> 37

<212> DNA

<213> Escherichia coli

<400> 24

gggctctccc atgcattcaa actgaggatc catcgat

37

<210> 25

<211> 50

<212> DNA

<213> Escherichia coli

<400> 25

tctagagcgg ccgcccggcg ggtcgccacc atgccgcgcg ctccccgctg

50

<210> 26

<211> 41

<212> DNA

<213> Escherichia coli

<400> 26

caaaatccca agcgtggcgc tgcccttaaa agcttatcga t

41

<210> 27

<211> 43

<212> DNA

<213> Escherichia coli

<400> 27

tctagagcgg ccgcccggcg ggtcgccacc atggtgagca agg

43

<210> 28

<211> 38

<212> DNA

<213> Escherichia coli

<400> 28

ctcggcatgg acgagctgta caataaaagc ttatcgat

38

Claims

1. A process for preparing reprogrammed mammalian cells *in vitro* without the use of a virus, comprising

a) providing isolated mammalian cells to be reprogrammed,

b) transfecting one or more reprogramming mRNA molecules into the cells provided in step a), wherein the reprogramming mRNA molecules are encoding at least one reprogramming protein selected from the group consisting of Ronin, Oct4, Klf4, Sox2, Nanog and TERT,

c) culturing the cells obtained in step b) in a cell culture medium and under a condition suitable to allow translation of the transfected reprogramming mRNA molecules, and wherein a condition suitable to allow translation of the transfected reprogramming mRNA molecules is a temperature from 30°C to 38°C and is an oxygen content in the cell culture medium from 0.5% to 21% and wherein the cell culture medium has a glucose content of 0.1 g/l to 4.6 g/l, so as to obtain reprogrammed cells, wherein said reprogrammed cells are mammalian cells exhibiting a pluripotent or multipotent stem cell character.

2. The process according to any one of the preceding claims, wherein the cell culture medium contains at least one inducing substance selected from the group consisting of reversine, resveratrol, selenium, selenium containing compounds, EGCG (epigallocatechin-3-gallate), valproic acid, salts of valproic acid and sodium valproate.

3. The process according to any one of the preceding claims, wherein the cell culture medium contains at least one transient proteolysis inhibitor.

4. The process according to claim 3, wherein the transient proteolysis inhibitor is selected from the group consisting of protease inhibitor, proteasome inhibitor and lysosome inhibitor.

5. The process according to any one of the preceding claims, wherein the cells to be reprogrammed are human cells.
6. A process for inducing the dedifferentiation of mammalian cells, wherein a process according to any one of claims 1 to 6 is carried out.

7. A process for improving the expansion of mammalian stem cells *in vitro*, wherein a process according to any one of claims 1 to 6 is carried out, comprising

- a) providing isolated mammalian cells to be reprogrammed,
- b) transfecting one or more reprogramming mRNA molecules into the cells provided in step a), wherein the reprogramming mRNA molecules are encoding at least one reprogramming protein selected from the group consisting of Ronin, Oct4, Klf4, Sox2, Nanog and TERT,
- c) culturing the cells obtained in step b) in a cell culture medium and under a condition suitable to allow translation of the transfected reprogramming mRNA molecules, and wherein a condition suitable to allow translation of the transfected reprogramming mRNA molecules is a temperature from 30°C to 38°C and is an oxygen content in the cell culture medium from 0.5% to 21% and wherein the cell culture medium has a glucose content of 0.1 g/l to 4.6 g/l, so as to obtain reprogrammed cells, wherein said reprogrammed cells are mammalian cells exhibiting a pluripotent or multipotent stem cell character,
- wherein said culturing in step c) is **characterized by** prolonging expansion of the pluripotent or multipotent stem cells obtained, whereby said stem cells to be expanded are kept in a dedifferentiated status.

8. A process for the rejuvenation of aged mammalian cells, wherein a process according to any one of claims 1 to 6 is carried out.




Fig. 1A





Fig. 1C





Fig. 1B

Amaya Elektroporation (klf4, sox2, oct4)




Fig. 2

Fugene Transfektion (klf4, sox2, oct4)




Fig. 3

RT-PCR für Oct4




Fig. 4

RT-PCR hOct4




Fig. 5

RT-PCR hOct4 and GAPDH




Fig. 6

RT-PCR hKlf4 and hNanog




Fig. 7




Fig. 8



EUROPEAN SEARCH REPORT

 Application Number
 EP 14 19 2115

5

10

15

20

25

30

35

40


45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
2 A	WO 2008/087442 A (EVOCELL LTD [GB]; JOHNSON ANDREW [GB]; ALBERIO RAMIRO [GB]) 24 July 2008 (2008-07-24) * page 33 - page 34; example 1 * * page 6 *	1-8	INV. C12N5/071
5 A	----- JAENISCH RUDOLF ET AL: "Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming", CELL, vol. 132, no. 4, February 2008 (2008-02), pages 567-582, XP009114628, ISSN: 0092-8674 * the whole document *	1-8	
6 A	----- TAKAHASHI K ET AL: "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 126, no. 4, 25 August 2006 (2006-08-25), pages 663-676, XP003013968, ISSN: 0092-8674 * the whole document *	1-8	TECHNICAL FIELDS SEARCHED (IPC) C12N
6 A	----- YU JUNYING ET AL: "Induced pluripotent stem cell lines derived from human somatic cells", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 318, no. 5858, 21 December 2007 (2007-12-21), pages 1917-1920, XP009105055, ISSN: 1095-9203 * the whole document *	1-8	
----- -/--			
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 28 March 2015	Examiner Paresce, Donata
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03.82 (P04C01)



EUROPEAN SEARCH REPORT

 Application Number
 EP 14 19 2115

5

10

15

20

25

30

35

40


45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
2 A	WO 2008/097926 A (UNIV YALE [US]; RABINOVICH PETER M [US]; WEISSMAN SHERMAN M [US]; KOMA) 14 August 2008 (2008-08-14) * page 1 - page 5 *	1-8	
5 A	DEJOSEZ MARION ET AL: "Ronin is essential for embryogenesis and the pluripotency of mouse embryonic stem cells (vol 133, pg 1162, 2008)", CELL, vol. 134, no. 4, August 2008 (2008-08), page 692, XP009114640, ISSN: 0092-8674 * page 1168 - page 1172 *	1-8	
6 A	ZUK P A ET AL: "Human adipose tissue is a source of multipotent stem cells", MOLECULAR BIOLOGY OF THE CELL, AMERICAN SOCIETY FOR CELL BIOLOGY, US, vol. 13, no. 12, 20 December 2002 (2002-12-20), pages 4279-4295, XP002249630, ISSN: 1059-1524, DOI: 10.1091/MBE.E02-02-0105 * the whole document *	1-8	
6 A	JULIANE M. WIEHE ET AL: "mRNA-Mediated Gene Delivery Into Human Progenitor Cells Promotes Highly Efficient Protein Expression", JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, vol. 11, no. 3, 1 May 2007 (2007-05-01), pages 521-530, XP055038624, ISSN: 1582-1838, DOI: 10.1111/j.1582-4934.2007.00038.x * the whole document *	1-8	TECHNICAL FIELDS SEARCHED (IPC)
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 28 March 2015	Examiner Paresce, Donata
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03.02 (P04-C01)



EUROPEAN SEARCH REPORT

 Application Number
EP 14 19 2115

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
6 A	CHUNG YOUNG ET AL: "Human embryonic stem cell lines generated without embryo destruction", CELL STEM CELL, ELSEVIER, CELL PRESS, AMSTERDAM, NL, vol. 2, no. 2, 7 February 2008 (2008-02-07), pages 113-117, XP002604696, ISSN: 1934-5909, DOI: 10.1016/J.STEM.2007.12.013 * the whole document *	1-8	
2 E	WO 2009/077134 A2 (UNIV MAINZ JOHANNES GUTENBERG [DE]; SAHIN UGUR [DE]; POLEGANOV MARCO []) 25 June 2009 (2009-06-25) * the whole document *	1-8	
2 E	WO 2009/093022 A2 (UNIV SHEFFIELD [GB]; NA JIE [GB]; ANDREWS PETER [GB]) 30 July 2009 (2009-07-30) * the whole document *	1-8	
6 T	ANTJE ARNOLD ET AL: "Reprogramming of Human Huntington Fibroblasts Using mRNA", ISRN CELL BIOLOGY,, vol. 2012, 1 January 2012 (2012-01-01), XP009164819, -----		
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (IPC)
Place of search Munich		Date of completion of the search 28 March 2015	Examiner Paresce, Donata
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03.82 (P04C01)

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 14 19 2115

5

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

28-03-2015

10

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2008087442 A	24-07-2008	NONE	
WO 2008097926 A	14-08-2008	US 2008260706 A1 WO 2008097926 A2	23-10-2008 14-08-2008
WO 2009077134 A2	25-06-2009	DK 2240572 T3 EP 2072618 A1 EP 2240572 A2 ES 2532125 T3 JP 2011505814 A US 2011065103 A1 WO 2009077134 A2	09-03-2015 24-06-2009 20-10-2010 24-03-2015 03-03-2011 17-03-2011 25-06-2009
WO 2009093022 A2	30-07-2009	NONE	

30

35

40

45

50

55

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 200710254884 A1 [0005]
- US 200710020759 A1 [0005]

Non-patent literature cited in the description

- **OKITA et al.** *Science*, 07 November 2008, vol. 322 (5903), 949-53 [0003]
- **ALTSCHUL, S.F. et al.** *J. Mol. Biol.*, 1990, vol. 215, 403 [0024]
- **ALTSCHUL, S.F. et al.** *Nucleic Acid Res.*, 1997, vol. 25, 3389-3402 [0024]
- **AUSUBEL et al.** *Current Protocols in Molecular Biology*. John Wiley & Sons Inc, 1994 [0030]